Compounds > jnj 7777120

Page last updated: 2024-12-10

jnj 7777120

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-((5-chloro-1H-indol-2-yl)carbonyl)-4-methylpiperazine: an H4 receptor antagonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	4908365
CHEMBL ID	129198
SCHEMBL ID	186434
MeSH ID	M0472856

Synonyms (49)

Synonym
gtpl1279
[3h]jnj 7777120
[3h]-jnj7777120
gtpl1278
chembl129198 ,
jnj 7777120
bdbm22566
5-chloro-2-[(4-methylpiperazin-1-yl)carbonyl]-1h-indole
NCGC00165814-01
STK175446 ,
(5-chloro-1h-indol-2-yl)(4-methylpiperazin-1-yl)methanone
1-((5-chloro-1h-indol-2-yl)carbonyl)-4-methylpiperazine
jnj7777120
jnj-7777120
(5-chloro-1h-indol-2-yl)-(4-methylpiperazin-1-yl)methanone
459168-41-3
4h1au2v37x ,
unii-4h1au2v37x
AKOS005410426
S2905
methanone, (5-chloro-1h-indol-2-yl)(4-methyl-1-piperazinyl)-
AB00815151-06
SCHEMBL186434
ES-0048
(5-chloro-1h-indol-2-yl)-(4-methyl-piperazin-1-yl)-metha none
(5-chloro-1h-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone
CS-4964
HY-13508
1-[(5-chloro-1h-indol-2-yl)carbonyl]-4-methylpiperazine
(5-chloro-1h-indol-2-yl)(4-methyl-1-piperazinyl)methanone
AC-32890
J-521699
5-chloro-2-(4-methylpiperazine-1-carbonyl)-1h-indole
jnj7777120, >=98% (hplc)
HMS3651L08
NCGC00165814-04
SW219424-1
FT-0747430
BCP06355
Q6108577
EX-A2082
SB19527
HMS3884L22
AMY40926
DTXSID20963461
CCG-267222
C75235
NCGC00165814-02
A872315

Research Excerpts

Bioavailability

Excerpt	Reference	Relevance
" This compound has an oral bioavailability of approximately 30% in rats and 100% in dogs, with a half-life of approximately 3 h in both species."	( A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties. Desai, PJ; Dunford, PJ; Edwards, JP; Fung-Leung, WP; Hofstra, CL; Jiang, W; Karlsson, L; Nguyen, S; Riley, JP; Sun, S; Thurmond, RL; Williams, KN, 2004)	0.32
"6 h, oral bioavailability of 37% and 90%) with anti-inflammatory activity (ED 50 = 37 micromol/kg, mouse) and efficacy in pain models (thermal hyperalgesia, ED 50 = 72 micromol/kg, rat)."	( Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models. Adair, RM; Altenbach, RJ; Bettencourt, BM; Brioni, JD; Cowart, MD; Drizin, I; Esbenshade, TA; Fix-Stenzel, SR; Honore, P; Hsieh, GC; Liu, H; Marsh, KC; McPherson, MJ; Milicic, I; Miller, TR; Sullivan, JP; Wetter, JM; Wishart, N; Witte, DG, 2008)	0.35
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Dosage Studied

Lymph nodes from animals dosed with the H(4)R antagonist, JNJ 7777120, contained a lower number of FITC-positive dendritic cells.

Excerpt	Relevance	Reference
" One explanation for this finding is that lymph nodes from animals dosed with the H(4)R antagonist, JNJ 7777120, contained a lower number of FITC-positive dendritic cells."	( The histamine H4 receptor mediates inflammation and pruritus in Th2-dependent dermal inflammation. Cowden, JM; Dunford, PJ; Thurmond, RL; Zhang, M, 2010)	0.58
" After inflammation was established mice were dosed with the H4R antagonist, JNJ 7777120, or anti-IL-13 antibody for comparison."	( Histamine H4 receptor antagonism diminishes existing airway inflammation and dysfunction via modulation of Th2 cytokines. Cowden, JM; Dunford, PJ; Ma, JY; Riley, JP; Thurmond, RL, 2010)	0.59
" Indeed, histamine elicited a sigmoid dose-response curve for IP3 production, shifted to the right by chlorpheniramine maleate, and elicited a double bell-shaped curve for cAMP production, partially suppressed by the selective H2R, H3R and H4R antagonists when each added alone, and completely ablated when combined together."	( Histamine receptor expression in human renal tubules: a comparative pharmacological evaluation. Camussi, G; Chazot, PL; Grange, C; Lanzi, C; Moggio, A; Pini, A; Rosa, AC; Veglia, E, 2015)	0.42

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (12)

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Histamine H2 receptor	Homo sapiens (human)	Ki	3.1000	0.0006	2.1973	10.0000	AID1798650; AID345935
Histamine H1 receptor	Cavia porcellus (domestic guinea pig)	Ki	3.5369	0.0026	1.7832	10.0000	AID1798212
Histamine H1 receptor	Homo sapiens (human)	Ki	5.4572	0.0000	0.5110	10.0000	AID1798212; AID1798650; AID345934; AID626411
Histamine H2 receptor	Cavia porcellus (domestic guinea pig)	Ki	3.5369	0.0007	1.0204	5.1250	AID1798212
Histamine H1 receptor	Mus musculus (house mouse)	Ki	3.5369	0.0007	1.6388	5.1250	AID1798212
Histamine H4 receptor	Rattus norvegicus (Norway rat)	Ki	1.8011	0.0024	0.9296	8.5110	AID1798212; AID1798650; AID1798651; AID1798682; AID345933; AID386755; AID390798; AID627801; AID638336; AID90041
Histamine H4 receptor	Mus musculus (house mouse)	IC50 (µMol)	0.0400	0.0400	0.0400	0.0400	AID671182
Histamine H4 receptor	Mus musculus (house mouse)	Ki	2.6645	0.0026	0.6978	5.1250	AID1649748; AID1649760; AID1798212; AID627802
Histamine H4 receptor	Cavia porcellus (domestic guinea pig)	Ki	1.0715	0.0060	0.3309	1.0715	AID627800
Histamine H4 receptor	Homo sapiens (human)	IC50 (µMol)	0.0909	0.0007	0.6305	10.0000	AID1178164; AID1638962; AID1735701; AID256876; AID256877; AID627793; AID627794; AID627795; AID627796; AID671181
Histamine H4 receptor	Homo sapiens (human)	Ki	0.7202	0.0006	0.4787	10.0000	AID1127886; AID1173695; AID1190702; AID1249560; AID1272171; AID1272172; AID1300612; AID1300613; AID1649705; AID1649747; AID1649753; AID1649754; AID1649755; AID1649756; AID1649757; AID1649758; AID1649759; AID1798212; AID1798265; AID1798650; AID1798651; AID1798682; AID239984; AID256865; AID266654; AID327691; AID345932; AID386754; AID390797; AID404336; AID408967; AID452843; AID452844; AID594143; AID626460; AID627669; AID627670; AID627797; AID630911; AID630917; AID632452; AID638335; AID638337; AID640805; AID640808; AID640809; AID671177; AID745776; AID89902
Histamine H3 receptor	Rattus norvegicus (Norway rat)	Ki	2.4455	0.0001	0.2963	8.5110	AID1798212; AID1798650; AID1798651; AID345937; AID390800
Histamine H3 receptor	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0005	0.4668	5.9000	AID1735708
Histamine H3 receptor	Homo sapiens (human)	Ki	3.9079	0.0001	0.3399	8.5110	AID1798212; AID1798266; AID1798650; AID1798651; AID239983; AID256878; AID345936; AID390799; AID632451; AID640810
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Histamine H4 receptor	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.2622	0.0026	1.0668	3.7153	AID1540383; AID386750; AID390807
Histamine H4 receptor	Mus musculus (house mouse)	EC50 (µMol)	0.3984	0.0024	2.0716	8.7096	AID1540382; AID386752
Histamine H4 receptor	Homo sapiens (human)	EC50 (µMol)	0.0179	0.0074	0.6016	10.0000	AID1178165; AID1573464; AID453003
Histamine H4 receptor	Homo sapiens (human)	Kd	0.0073	0.0040	0.0194	0.0702	AID239856; AID256866; AID745204; AID90031
Histamine H3 receptor	Homo sapiens (human)	EC50 (µMol)	1.0000	0.0000	0.0947	3.1623	AID243150
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Histamine H1 receptor	Cavia porcellus (domestic guinea pig)	Kb	0.0028	0.0028	0.0028	0.0028	AID1638965
Prostaglandin G/H synthase 2	Homo sapiens (human)	Kb	0.0120	0.0120	0.0347	0.0620	AID471111
Prostaglandin G/H synthase 2	Homo sapiens (human)	Kinact	0.0160	0.0130	0.0513	0.1250	AID471111
Histamine H4 receptor	Homo sapiens (human)	Kb	0.0157	0.0028	0.0385	0.1000	AID1300590; AID1300597; AID1638965; AID471111
Histamine H4 receptor	Homo sapiens (human)	Kinact	0.0160	0.0130	0.0513	0.1250	AID471111
Histamine H3 receptor	Homo sapiens (human)	Kb	2.0000	0.0002	0.2097	2.0000	AID1300581
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (76)

Process	via Protein(s)	Taxonomy
gastric acid secretion	Histamine H2 receptor	Homo sapiens (human)
immune response	Histamine H2 receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Histamine H2 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Histamine H2 receptor	Homo sapiens (human)
chemical synaptic transmission	Histamine H2 receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Histamine H2 receptor	Homo sapiens (human)
prostaglandin biosynthetic process	Prostaglandin G/H synthase 2	Homo sapiens (human)
angiogenesis	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to oxidative stress	Prostaglandin G/H synthase 2	Homo sapiens (human)
embryo implantation	Prostaglandin G/H synthase 2	Homo sapiens (human)
learning	Prostaglandin G/H synthase 2	Homo sapiens (human)
memory	Prostaglandin G/H synthase 2	Homo sapiens (human)
regulation of blood pressure	Prostaglandin G/H synthase 2	Homo sapiens (human)
negative regulation of cell population proliferation	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to xenobiotic stimulus	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to nematode	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to fructose	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to manganese ion	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of vascular endothelial growth factor production	Prostaglandin G/H synthase 2	Homo sapiens (human)
cyclooxygenase pathway	Prostaglandin G/H synthase 2	Homo sapiens (human)
bone mineralization	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of prostaglandin biosynthetic process	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of fever generation	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of synaptic plasticity	Prostaglandin G/H synthase 2	Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergic	Prostaglandin G/H synthase 2	Homo sapiens (human)
prostaglandin secretion	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to estradiol	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to lipopolysaccharide	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to vitamin D	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to heat	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to tumor necrosis factor	Prostaglandin G/H synthase 2	Homo sapiens (human)
maintenance of blood-brain barrier	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of protein import into nucleus	Prostaglandin G/H synthase 2	Homo sapiens (human)
hair cycle	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of apoptotic process	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of nitric oxide biosynthetic process	Prostaglandin G/H synthase 2	Homo sapiens (human)
negative regulation of cell cycle	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of vasoconstriction	Prostaglandin G/H synthase 2	Homo sapiens (human)
negative regulation of smooth muscle contraction	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of smooth muscle contraction	Prostaglandin G/H synthase 2	Homo sapiens (human)
decidualization	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Prostaglandin G/H synthase 2	Homo sapiens (human)
regulation of inflammatory response	Prostaglandin G/H synthase 2	Homo sapiens (human)
brown fat cell differentiation	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to glucocorticoid	Prostaglandin G/H synthase 2	Homo sapiens (human)
negative regulation of calcium ion transport	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to fatty acid	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to mechanical stimulus	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to lead ion	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to ATP	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to hypoxia	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to non-ionic osmotic stress	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to fluid shear stress	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of transforming growth factor beta production	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesis	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of fibroblast growth factor production	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of brown fat cell differentiation	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of platelet-derived growth factor production	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular oxidant detoxification	Prostaglandin G/H synthase 2	Homo sapiens (human)
regulation of neuroinflammatory response	Prostaglandin G/H synthase 2	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to homocysteine	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to angiotensin	Prostaglandin G/H synthase 2	Homo sapiens (human)
inflammatory response	Histamine H1 receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Histamine H1 receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Histamine H1 receptor	Homo sapiens (human)
memory	Histamine H1 receptor	Homo sapiens (human)
visual learning	Histamine H1 receptor	Homo sapiens (human)
regulation of vascular permeability	Histamine H1 receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Histamine H1 receptor	Homo sapiens (human)
regulation of synaptic plasticity	Histamine H1 receptor	Homo sapiens (human)
cellular response to histamine	Histamine H1 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Histamine H1 receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Histamine H1 receptor	Homo sapiens (human)
chemical synaptic transmission	Histamine H1 receptor	Homo sapiens (human)
inflammatory response	Histamine H4 receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Histamine H4 receptor	Homo sapiens (human)
biological_process	Histamine H4 receptor	Homo sapiens (human)
regulation of MAPK cascade	Histamine H4 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Histamine H4 receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Histamine H4 receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Histamine H4 receptor	Homo sapiens (human)
chemical synaptic transmission	Histamine H4 receptor	Homo sapiens (human)
neurotransmitter secretion	Histamine H3 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Histamine H3 receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Histamine H3 receptor	Homo sapiens (human)
chemical synaptic transmission	Histamine H3 receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Histamine H3 receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Process	via Protein(s)	Taxonomy
histamine receptor activity	Histamine H2 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Histamine H2 receptor	Homo sapiens (human)
neurotransmitter receptor activity	Histamine H2 receptor	Homo sapiens (human)
peroxidase activity	Prostaglandin G/H synthase 2	Homo sapiens (human)
prostaglandin-endoperoxide synthase activity	Prostaglandin G/H synthase 2	Homo sapiens (human)
protein binding	Prostaglandin G/H synthase 2	Homo sapiens (human)
enzyme binding	Prostaglandin G/H synthase 2	Homo sapiens (human)
heme binding	Prostaglandin G/H synthase 2	Homo sapiens (human)
protein homodimerization activity	Prostaglandin G/H synthase 2	Homo sapiens (human)
metal ion binding	Prostaglandin G/H synthase 2	Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen	Prostaglandin G/H synthase 2	Homo sapiens (human)
histamine receptor activity	Histamine H1 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Histamine H1 receptor	Homo sapiens (human)
neurotransmitter receptor activity	Histamine H1 receptor	Homo sapiens (human)
histamine receptor activity	Histamine H4 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Histamine H4 receptor	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Histamine H4 receptor	Homo sapiens (human)
histamine receptor activity	Histamine H3 receptor	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Histamine H3 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Histamine H3 receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Process	via Protein(s)	Taxonomy
plasma membrane	Histamine H2 receptor	Homo sapiens (human)
synapse	Histamine H2 receptor	Homo sapiens (human)
plasma membrane	Histamine H2 receptor	Homo sapiens (human)
dendrite	Histamine H2 receptor	Homo sapiens (human)
nuclear inner membrane	Prostaglandin G/H synthase 2	Homo sapiens (human)
nuclear outer membrane	Prostaglandin G/H synthase 2	Homo sapiens (human)
cytoplasm	Prostaglandin G/H synthase 2	Homo sapiens (human)
endoplasmic reticulum	Prostaglandin G/H synthase 2	Homo sapiens (human)
endoplasmic reticulum lumen	Prostaglandin G/H synthase 2	Homo sapiens (human)
endoplasmic reticulum membrane	Prostaglandin G/H synthase 2	Homo sapiens (human)
caveola	Prostaglandin G/H synthase 2	Homo sapiens (human)
neuron projection	Prostaglandin G/H synthase 2	Homo sapiens (human)
protein-containing complex	Prostaglandin G/H synthase 2	Homo sapiens (human)
neuron projection	Prostaglandin G/H synthase 2	Homo sapiens (human)
cytoplasm	Prostaglandin G/H synthase 2	Homo sapiens (human)
cytosol	Histamine H1 receptor	Homo sapiens (human)
plasma membrane	Histamine H1 receptor	Homo sapiens (human)
synapse	Histamine H1 receptor	Homo sapiens (human)
dendrite	Histamine H1 receptor	Homo sapiens (human)
plasma membrane	Histamine H1 receptor	Homo sapiens (human)
plasma membrane	Histamine H4 receptor	Homo sapiens (human)
plasma membrane	Histamine H4 receptor	Homo sapiens (human)
dendrite	Histamine H4 receptor	Homo sapiens (human)
synapse	Histamine H4 receptor	Homo sapiens (human)
plasma membrane	Histamine H3 receptor	Homo sapiens (human)
presynapse	Histamine H3 receptor	Homo sapiens (human)
plasma membrane	Histamine H3 receptor	Homo sapiens (human)
synapse	Histamine H3 receptor	Homo sapiens (human)
dendrite	Histamine H3 receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (255)

Assay ID	Title	Year	Journal	Article
AID1300576	Agonist activity at human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 assessed as increase in 32Pi level preincubated for 2 mins followed by [gamma-32P]GTP addition measured after 20 mins by liquid scintillation counting method	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.
AID390776	Half life in mouse at 5 mg/kg, iv	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID640810	Binding affinity to human histamine H3 receptor	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Synthesis of novel histamine H4 receptor antagonists.
AID627798	Displacement of [3H]-histamine from macaque H4R expressed in HEK293T cells	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
AID627796	Antagonist activity at H4R in human eosinophils assessed as inhibition of imetit-induced shape change by GAFS assay	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
AID1540382	Agonist activity at mouse H4R by [35S]-GTPgammaS-binding assay
AID391066	Plasma concentration in rat at 30 umol/kg, ip	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID390768	Plasma clearance in mouse at 5 mg/kg, iv	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID256873	Area under curve in rat administered with 10 mg/kg, po	2005	Journal of medicinal chemistry, Dec-29, Volume: 48, Issue:26	Preparation and biological evaluation of indole, benzimidazole, and thienopyrrole piperazine carboxamides: potent human histamine h(4) antagonists.
AID390783	Bioavailability in rat at 10 mg/kg, po	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID386758	Selectivity ratio of Ki for human histamine H4 receptor to Ki for histamine H2 receptor	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID1638972	Antinociceptive activity in formalin-induced nociception pain Albino Swiss CD-1 mouse model assessed as reduction in time spent licking or biting formalin injected right hind paw in early phase at 25 mg/kg, ip pretreated followed by formalin injection and	2019	Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7	Alkyl derivatives of 1,3,5-triazine as histamine H
AID386752	Antagonist activity at mouse histamine H4 receptor expressed in HEK293 cells assessed as inhibition of histamine-induced intracellular calcium elevation by FLIPR assay	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID256868	In vitro half life in human S9 fraction	2005	Journal of medicinal chemistry, Dec-29, Volume: 48, Issue:26	Preparation and biological evaluation of indole, benzimidazole, and thienopyrrole piperazine carboxamides: potent human histamine h(4) antagonists.
AID1649758	Displacement of UR-DEBa176 from human recombinant H4R expressed in HEK293T-SF-His6-CRE-Luc cells
AID453003	Inverse agonist activity at human histamine H4 receptor expressed in Sf9 cells co-expressing Galphai2 and Gbeta1gamma2 assessed as stimulation of [35S]GTPgammaS binding	2009	Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20	2,4-Diaminopyrimidines as histamine H4 receptor ligands--Scaffold optimization and pharmacological characterization.
AID626411	Displacement of [3H]mepyramine from human H1R expressed in Sf9 cells co-expressing RGS4 after 90 mins by liquid scintillation counting	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH(1)R, but low affinity to hH(4)R.
AID386810	Inhibition of clobenpropit-induced itching in ip dosed CD1/ICR mouse assessed as blockade of scratching in hind paw for 25 mins pretreated 30 mins before clobenpropit challenge	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID390798	Displacement of [3H]histamine from rat histamine H4 receptor expressed in HEK293 cells	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID627671	Lipophilicity, log D of the compound	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
AID640816	Half life in rat at 3 mg/kg, sc	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Synthesis of novel histamine H4 receptor antagonists.
AID1638973	Antinociceptive activity in formalin-induced nociception pain Albino Swiss CD-1 mouse model assessed as reduction in time spent licking or biting formalin injected right hind paw in inflammatory phase at 25 mg/kg, ip pretreated followed by formalin inject	2019	Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7	Alkyl derivatives of 1,3,5-triazine as histamine H
AID1735709	Intrinsic clearance in CD1 mouse liver microsomes at 5 uM incubated upto 30 mins in presence of NADPH by UPLC-UV analysis	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of a Novel Highly Selective Histamine H4 Receptor Antagonist for the Treatment of Atopic Dermatitis.
AID640809	Antagonist activity at human histamine H4 receptor expressed in HEK293 cells assessed as rev inhibition of forskolin-stimulated cAMP accumulation by CRE-betalactamase reporter gene assay	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Synthesis of novel histamine H4 receptor antagonists.
AID391068	Protein binding in ip dosed rat plasma	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID640805	Binding affinity to human histamine H4 receptor	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Synthesis of novel histamine H4 receptor antagonists.
AID239983	Binding affinity towards human histamine H3 receptor was determined by [3H]Na-methylhistamine binding to SK-N-MC cell membranes	2004	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21	Synthesis and structure-activity relationships of indole and benzimidazole piperazines as histamine H(4) receptor antagonists.
AID638590	Displacement of [3H]histamine from human H4R assessed as binding half life	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	Ligand based design of novel histamine H₄ receptor antagonists; fragment optimization and analysis of binding kinetics.
AID390799	Binding affinity to human histamine H3 receptor	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID391064	Antiinflammatory activity against carrageenan-induced thermal hyperalgesia in ip dosed rat assessed as increase in paw withdrawal	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID745775	Aqueous solubility of the compound at pH 6.8 by automated polarized light microscopy analysis	2013	Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11	Bispyrimidines as potent histamine H(4) receptor ligands: delineation of structure-activity relationships and detailed H(4) receptor binding mode.
AID391073	Plasma concentration in rat at 300 umol/kg, ip	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID390772	Cmax in mouse at 5 mg/kg, iv	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID626460	Displacement of [3H]histamine from human H4R expressed in Sf9 cells co-expressing RGS19, Galphai2 and Gbeta1gamma2 after 60 mins by liquid scintillation counting	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH(1)R, but low affinity to hH(4)R.
AID390797	Displacement of [3H]histamine from human histamine H4 receptor expressed in HEK293 cells	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID390808	Agonist activity at rat histamine H4 receptor expressed in HEK293 cells coexpressing Gqi5 protein by GTPgammaS assay relative to histamine	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID386762	Selectivity ratio of Ki for human histamine H4 receptor to Ki for 5HT2A receptor	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID632451	Displacement of [3H]histamine from human H3 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting	2011	Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23	Molecular determinants of ligand binding modes in the histamine H(4) receptor: linking ligand-based three-dimensional quantitative structure-activity relationship (3D-QSAR) models to in silico guided receptor mutagenesis studies.
AID390805	Plasma concentration in mouse at 25 umol/kg, ip after 30 mins	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID386796	Blood clearance in rat at 10 mg/kg, iv	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID627985	Agonist activity at macaque H4R expressed in HEK293T cells assessed as reversal of forskolin-induced cAMP production by CRE-beta-lactamase reporter gene assay	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
AID390763	Terminal volume of distribution in rat at 10 mg/kg, iv	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID1540383	Agonist activity at rat H4R by [35S]-GTPgammaS-binding assay
AID390791	Half life in rat at 10 mg/kg, po	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID386764	Selectivity ratio of Ki for human histamine H4 receptor to Ki for adrenergic alpha1 receptor	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID391075	Antagonist activity at histamine H3 receptor by GTPgammaS assay	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID345934	Binding affinity to human histamine H1 receptor	2008	Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
AID745776	Displacement of [3H]histamine displacement from human recombinant histamine H4 receptor expressed in SK-NM-C cells after 45 mins	2013	Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11	Bispyrimidines as potent histamine H(4) receptor ligands: delineation of structure-activity relationships and detailed H(4) receptor binding mode.
AID1638980	Anti-inflammatory activity in Wistar (Krf:(WI) WU) rat model of carrageenan-induced paw edema assessed as hind paw volume at 25 mg/kg, ip administered as single dose prior to carrageenan challenge and measured after 2 hrs by plethysmometer (Rvb = 103%)	2019	Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7	Alkyl derivatives of 1,3,5-triazine as histamine H
AID386782	Cmax in mouse at 5 mg/kg, iv	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID1300582	Agonist activity at human histamine H2 receptor expressed in sf9 cell membrane co-expressing Gsalphas incubated for 90 mins by [35S]GTPgammaS binding assay	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.
AID1300580	Intrinsic activity at human histamine H2 receptor expressed in sf9 cell membrane co-expressing Gsalphas at 10 uM incubated for 90 mins by [35S]GTPgammaS binding assay relative to histamine	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.
AID627983	Antagonist activity at human H4R expressed in HEK293T cells assessed as reversal of forskolin-induced cAMP production by CRE-beta-lactamase reporter gene assay	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
AID452843	Binding affinity to histamine H4 receptor	2009	Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20	2,4-Diaminopyrimidines as histamine H4 receptor ligands--Scaffold optimization and pharmacological characterization.
AID627676	Half life in rat at 10 mg/kg, po	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
AID630917	Displacement of [3H]histamine from human histamine H4 receptor expressed in CHO cells after 90 mins by scintillation counting technique	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Discovery of a series of potent and selective human H4 antagonists using ligand efficiency and libraries to explore structure-activity relationship (SAR).
AID327691	Displacement of [3H]histamine from human histamine H4 receptor expressed in HEK293T cells	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	Fragment based design of new H4 receptor-ligands with anti-inflammatory properties in vivo.
AID386799	Half life in mouse at 5 mg/kg, iv	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID626461	Antagonist activity at H1R in guinea pig ileum assessed as inhibition of histamine-induced muscle contraction after 15 mins	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH(1)R, but low affinity to hH(4)R.
AID1638987	Anti-inflammatory activity in Wistar (Krf:(WI) WU) rat model of carrageenan-induced thermal hyperalgesia assessed as paw withdrawal latency time at 25 mg/kg, ip administered as single dose prior to carrageenan challenge and measured after 1 hr by plantar	2019	Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7	Alkyl derivatives of 1,3,5-triazine as histamine H
AID1735708	Displacement of [3H]-N-alpha-methylhistamine from recombinant human histamine H3 receptor expressed in CHO-K1 cell membranes measured after 30 mins by microbeta scintillation counting method	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of a Novel Highly Selective Histamine H4 Receptor Antagonist for the Treatment of Atopic Dermatitis.
AID471111	Antagonist activity at human histamine H4 receptor expressed in Sf9 cell membrane coexpressing RGS19 protein assessed as inhibition of 2-Cyano-1-[4-(1H-imidazol-4-yl)butyl]-3-(2-phenylthioethyl)-guanidine-stimulated GTP hydrolysis by steady-state GTPase a	2009	Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20	Synthesis and structure-activity relationships of cyanoguanidine-type and structurally related histamine H4 receptor agonists.
AID386761	Selectivity ratio of Ki for human histamine H4 receptor to Ki for 5HT1D receptor	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID627670	Antagonist activity at full length human H4R expressed in HEK293 cells assessed as reversal of forskolin-induced cAMP production by CRE-beta-lactamase reporter gene assay	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
AID256877	Inhibition of human eosinophil chemotaxis mediated by histamine H4 receptor	2005	Journal of medicinal chemistry, Dec-29, Volume: 48, Issue:26	Preparation and biological evaluation of indole, benzimidazole, and thienopyrrole piperazine carboxamides: potent human histamine h(4) antagonists.
AID386778	Protein binding in human	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID256878	Binding affinity to histamine H3 receptor	2005	Journal of medicinal chemistry, Dec-29, Volume: 48, Issue:26	Preparation and biological evaluation of indole, benzimidazole, and thienopyrrole piperazine carboxamides: potent human histamine h(4) antagonists.
AID1190702	Displacement of [3H]histamine from human recombinant histamine H4 receptor	2015	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 25, Issue:4	Diaminopyrimidines, diaminopyridines and diaminopyridazines as histamine H4 receptor modulators.
AID256874	Oral bioavailability in rat administered with 10 mg/kg, po	2005	Journal of medicinal chemistry, Dec-29, Volume: 48, Issue:26	Preparation and biological evaluation of indole, benzimidazole, and thienopyrrole piperazine carboxamides: potent human histamine h(4) antagonists.
AID390771	Cmax in rat at 10 mg/kg, iv	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID1573464	Agonist activity at histamine H4 receptor (unknown origin) assessed as increase in beta-arrestin recruitment	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID1735711	Solubility of compound in SGF at pH 1.2 incubated for 2 hrs by UPLC-UV analysis	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of a Novel Highly Selective Histamine H4 Receptor Antagonist for the Treatment of Atopic Dermatitis.
AID745774	Half life in human liver microsomes	2013	Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11	Bispyrimidines as potent histamine H(4) receptor ligands: delineation of structure-activity relationships and detailed H(4) receptor binding mode.
AID386802	Fractional bioavailability in rat at 5 mg/kg, iv and 5 mg/kg, po	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID386754	Displacement of [3H]histamine from human histamine H4 receptor expressed in HEK293 cells	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID386781	Inhibition of CYP2C9 upto 10 uM	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID390759	Antagonist activity at human histamine H4 receptor expressed in HEK293 cells coexpressing Gqi5 protein assessed as calcium flux by FLIPR assay	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID243150	Effective concentration required against human histamine H3 receptor was determined by the inhibition of the cAMP stimulated beta-galactosidase transcription in SK-N-MC cells	2004	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21	Synthesis and structure-activity relationships of indole and benzimidazole piperazines as histamine H(4) receptor antagonists.
AID638335	Binding affinity to human histamine H4 receptor	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	Ligand based design of novel histamine H₄ receptor antagonists; fragment optimization and analysis of binding kinetics.
AID1638981	Anti-inflammatory activity in Wistar (Krf:(WI) WU) rat model of carrageenan-induced paw edema assessed as hind paw volume at 25 mg/kg, ip administered as single dose prior to carrageenan challenge and measured after 3 hrs by plethysmometer (Rvb = 130%)	2019	Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7	Alkyl derivatives of 1,3,5-triazine as histamine H
AID256872	Half life in rat administered with 10 mg/kg, po	2005	Journal of medicinal chemistry, Dec-29, Volume: 48, Issue:26	Preparation and biological evaluation of indole, benzimidazole, and thienopyrrole piperazine carboxamides: potent human histamine h(4) antagonists.
AID1638979	Anti-inflammatory activity in Wistar (Krf:(WI) WU) rat model of carrageenan-induced paw edema assessed as hind paw volume at 25 mg/kg, ip administered as single dose prior to carrageenan challenge and measured after 1 hr by plethysmometer (Rvb = 49%)	2019	Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7	Alkyl derivatives of 1,3,5-triazine as histamine H
AID386750	Antagonist activity at rat histamine H4 receptor expressed in HEK293 cells assessed as inhibition of histamine-induced intracellular calcium elevation by FLIPR assay	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID1540384	Antagonist activity at human H4R by [35S]-GTPgammaS-binding assay
AID386777	Protein binding in rat	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID627669	Displacement of [3H]-histamine from full length human H4R expressed in HEK293 cells	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
AID627997	Metabolic stability in rat liver microsomes	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
AID1649761	Antagonist activity at mouse recombinant H4R expressed in HEK293T-SF-His6-CRE-Luc cells by luciferase reporter gene assay
AID386756	Blockade of histamine-induced morphological changes in BALB/c mouse BMMC by flow cytometry	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID408967	Displacement of [3H]histamine from human histamine H4 receptor expressed in HEK cells	2008	Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24	Discovery of quinazolines as histamine H4 receptor inverse agonists using a scaffold hopping approach.
AID390775	Half life in rat at 10 mg/kg, iv	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID640806	Intrinsic clearance in rat	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Synthesis of novel histamine H4 receptor antagonists.
AID390802	Antiinflammatory activity in zymosan-induced peritonitis in sc dosed BALB/c mouse model assessed as decrease in myeloperoxidase activity in peritoneal lavage	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID627675	Metabolic stability in rat liver microsomes assessed as half life	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
AID1649705	Displacement of [3H]-histamine from Galphai2/Gbeta1gamma2-coupled human recombinant H4R expressed in baculovirus infected Sf9 insect cell membranes
AID386790	Tmax in mouse at 20 mg/kg, sc	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID452844	Displacement of [3H]histamine from human histamine H4 receptor expressed in Sf9 cells co-expressing Galphai2 and Gbeta1gamma2	2009	Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20	2,4-Diaminopyrimidines as histamine H4 receptor ligands--Scaffold optimization and pharmacological characterization.
AID386795	Half life in rat at 10 mg/kg, iv	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID1300613	Displacement of [3H]histamine from human histamine H4 receptor expressed in sf9 cells co-expressing mammalian Galphai2 and Gbeta1gamma2	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.
AID1638988	Anti-inflammatory activity in Wistar (Krf:(WI) WU) rat model of carrageenan-induced thermal hyperalgesia assessed as paw withdrawal latency time at 25 mg/kg, ip administered as single dose prior to carrageenan challenge and measured after 2 hrs by plantar	2019	Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7	Alkyl derivatives of 1,3,5-triazine as histamine H
AID1300589	Intrinsic activity at human histamine H4 receptor expressed in sf9 cell membrane co-expressing mammalian Galphai2 and Gbeta1gamma2 at 10 uM incubated for 90 mins by [35S]GTPgammaS binding assay relative to histamine	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.
AID345929	Antagonist activity at rat histamine H4 receptor assessed as inhibition of histamine-induced intracellular calcium level by FLIPR	2008	Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
AID386757	Selectivity ratio of Ki for human histamine H4 receptor to Ki for histamine H1 receptor	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID390788	Cmax in mouse at 20 mg/kg, po	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID1735712	Solubility of compound in FaSSIF at pH 1.2 incubated for 0.5 hrs by UPLC-UV analysis	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of a Novel Highly Selective Histamine H4 Receptor Antagonist for the Treatment of Atopic Dermatitis.
AID1249560	Binding affinity to human histamine H4 receptor	2015	Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18	Functional Profiling of 2-Aminopyrimidine Histamine H4 Receptor Modulators.
AID386785	AUC (0 to t) in mouse at 5 mg/kg, iv	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID1173695	Displacement of [3H]histamine from human recombinant histamine H4 receptor	2014	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23	The effect of pK(a) on pyrimidine/pyridine-derived histamine H4 ligands.
AID627793	Antagonist activity at H4R in human eosinophils assessed as inhibition of histamine-induced shape change by GAFS assay	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
AID386794	Oral bioavailability in mouse at 20 mg/kg, sc	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID627987	Agonist activity at dog H4R expressed in HEK293T cells assessed as reversal of forskolin-induced cAMP production by CRE-beta-lactamase reporter gene assay	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
AID386774	Metabolic stability in rat liver microsomes	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID391070	Plasma concentration in rat at 80 umol/kg, ip	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID594143	Displacement of [3H]histamine from human histamine H4 receptor	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	Triamino pyrimidines and pyridines as histamine H(4) receptor modulators.
AID391072	Antiinflammatory activity against carrageenan-induced hyperalgesia in rat assessed as increase in paw withdrawal by measuring plasma free fraction potency	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID386755	Displacement of [3H]histamine from rat histamine H4 receptor expressed in HEK293 cells	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID1300590	Antagonist activity at human histamine H4 receptor expressed in sf9 cell membrane co-expressing mammalian Galphai2 and Gbeta1gamma2 assessed as inhibition of histamine-induced [35S]GTPgammaS binding incubated for 90 mins	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.
AID386809	Antiinflammatory activity against ip dosed BALB/c mouse assessed as inhibition of zymosan-induced peritonitis after 2 hrs pretreated 30 mins before zymosan challenge	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID386760	Selectivity ratio of Ki for human histamine H4 receptor to Ki for 5HT1A receptor	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID627991	Agonist activity at rat H4R expressed in HEK293T cells assessed as reversal of forskolin-induced cAMP production by CRE-beta-lactamase reporter gene assay	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
AID391071	Antiinflammatory activity against carrageenan-induced hyperalgesia in rat assessed as increase in paw withdrawal at 300 umol/kg, ip relative to control	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID1638965	Antagonist activity at recombinant human H4 receptor expressed in Sf9 cell membranes co-expressing Galphai2/Gbeta1gamma2 assessed as inhibition of histamine-induced response measured after 1 hr in presence of [35S]GTPgammaS by liquid scintillation countin	2019	Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7	Alkyl derivatives of 1,3,5-triazine as histamine H
AID390784	Bioavailability in mouse at 20 mg/kg, po	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID1638986	Anti-inflammatory activity in Wistar (Krf:(WI) WU) rat model of carrageenan-induced mechanical hyperalgesia assessed as increase in paw withdrawal threshold at 25 mg/kg, ip administered as single dose prior to carrageenan challenge and measured after 3 hr	2019	Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7	Alkyl derivatives of 1,3,5-triazine as histamine H
AID386775	Metabolic stability in human liver microsomes	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID386798	Fractional bioavailability in rat at 10 mg/kg, iv and 10 mg/kg, po	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID390809	Inhibition of histamine-induced shape change in BALB/c mouse BMMC by gated autofluorescence forward scatter	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID1638962	Antagonist activity at recombinant human H4 receptor expressed in CHOK1 cells co-expressing Galpha16/aequorin assessed as inhibition of histamine-induced intracellular calcium flux preincubated for 30 mins followed by histamine addition and measured for 3	2019	Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7	Alkyl derivatives of 1,3,5-triazine as histamine H
AID386789	Cmax in mouse at 20 mg/kg, sc	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID1649747	Inhibition of UR-DEBa242 binding to human recombinant NLuc/GPCR-fused H4R expressed in HEK293T cells measured after 30 mins by furimazine substrate based BRET assay
AID244406	Intrinsic activity against human histamine H3 receptor	2004	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21	Synthesis and structure-activity relationships of indole and benzimidazole piperazines as histamine H(4) receptor antagonists.
AID386788	Plasma clearance in mouse at 5 mg/kg, iv	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID1649760	Displacement of UR-DEBa176 from mouse recombinant H4R expressed in HEK293T-SF-His6-CRE-Luc cells
AID640811	Metabolic stability in human liver microsomes	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Synthesis of novel histamine H4 receptor antagonists.
AID626465	Antagonist activity at human H4R expressed in Sf9 cells co-expressing RGS19, Galphai2 and Gbeta1gamma2 assessed as inhibition of histamine-induced [35S]GTPgammaS binding relative to histamine	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH(1)R, but low affinity to hH(4)R.
AID256871	Maximum concentration in rat administered with 10 mg/kg, po	2005	Journal of medicinal chemistry, Dec-29, Volume: 48, Issue:26	Preparation and biological evaluation of indole, benzimidazole, and thienopyrrole piperazine carboxamides: potent human histamine h(4) antagonists.
AID386807	Ratio of drug level in brain to plasma in rat at 30 mg/kg, iv after 30 mins	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID345935	Binding affinity to human histamine H2 receptor	2008	Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
AID391074	Unbound fraction in rat plasma at 80 umol/kg, ip	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID1127886	Displacement of [3H]histamine from human recombinant histamine H4 receptor expressed in SK-N-MC cells after 45 mins by competition binding analysis	2014	Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6	Discovery and SAR of 6-alkyl-2,4-diaminopyrimidines as histamine H₄ receptor antagonists.
AID345936	Binding affinity to human histamine H3 receptor	2008	Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
AID390800	Binding affinity to rat histamine H3 receptor	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID1649754	Displacement of [3H]-UR-PI294 from Galphai2/Gbeta1gamma2-coupled human recombinant H4R expressed in baculovirus infected Sf9 insect cell membranes co-expressing RGS19 measured after 60 mins by microbeta scintillation counting method
AID256866	Antagonistic activity at human histamine H4 receptor in SK-N-MC cells by inhibition of forskolin-stimulated cAMP-mediated reporter gene activity	2005	Journal of medicinal chemistry, Dec-29, Volume: 48, Issue:26	Preparation and biological evaluation of indole, benzimidazole, and thienopyrrole piperazine carboxamides: potent human histamine h(4) antagonists.
AID256876	Inhibition of mouse bone-marrow mast cell chemotaxis mediated by histamine H4 receptor	2005	Journal of medicinal chemistry, Dec-29, Volume: 48, Issue:26	Preparation and biological evaluation of indole, benzimidazole, and thienopyrrole piperazine carboxamides: potent human histamine h(4) antagonists.
AID632452	Displacement of [3H]histamine from human H4 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting	2011	Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23	Molecular determinants of ligand binding modes in the histamine H(4) receptor: linking ligand-based three-dimensional quantitative structure-activity relationship (3D-QSAR) models to in silico guided receptor mutagenesis studies.
AID1300597	Antagonist activity at human histamine H4 receptor expressed in sf9 cell membrane co-expressing mammalian Galphai2 and Gbeta1gamma2 assessed as inhibition of UR-RG98-induced [35S]GTPgammaS binding incubated for 90 mins	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.
AID386800	Blood clearance in mouse at 5 mg/kg, iv	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID627802	Displacement of [3H]-histamine from mouse H4R expressed in HEK293T cells	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
AID627989	Agonist activity at guinea pig H4R expressed in HEK293T cells assessed as reversal of forskolin-induced cAMP production by CRE-beta-lactamase reporter gene assay	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
AID256867	In vitro half life in human liver microsomes	2005	Journal of medicinal chemistry, Dec-29, Volume: 48, Issue:26	Preparation and biological evaluation of indole, benzimidazole, and thienopyrrole piperazine carboxamides: potent human histamine h(4) antagonists.
AID627996	Metabolic stability in human liver microsomes	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
AID627992	Partial agonist activity at mouse H4R expressed in HEK293T cells assessed as reversal of forskolin-induced cAMP production by CRE-beta-lactamase reporter gene assay	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
AID1649757	Displacement of [3H]-histamine from human recombinant H4R expressed in HEK293T cell homogenates
AID627799	Displacement of [3H]-histamine from dog H4R expressed in HEK293T cells	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
AID627673	Apparent permeability from basolateral to apical side of human Caco2 cells	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
AID90031	Decrease in the forskolin stimulatedcAMP levels was determined using SK-N-MC cells stably transfected with the human H4 receptor	2003	Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19	The first potent and selective non-imidazole human histamine H4 receptor antagonists.
AID640808	Displacement of [3H]histamine from human recombinant histamine H4 receptor expressed in CHO cells coexpressing Ga15 by radioligand filtration binding assay	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Synthesis of novel histamine H4 receptor antagonists.
AID390780	Tmax in mouse at 20 mg/kg, po	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID390794	Antagonist activity at mouse histamine H4 receptor expressed in HEK293 cells coexpressing Gqi5 protein assessed as calcium flux by FLIPR assay	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID627794	Antagonist activity at H4R in human eosinophils assessed as inhibition of histamine-induced CD11b upregulation	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
AID745204	Displacement of [3H]histamine from human histamine H4 receptor expressed in HEK cells by competitive kinetic analysis	2013	Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9	A novel series of histamine H4 receptor antagonists based on the pyrido[3,2-d]pyrimidine scaffold: comparison of hERG binding and target residence time with PF-3893787.
AID1735710	Intrinsic clearance in human liver microsomes at 5 uM incubated upto 30 mins in presence of NADPH by UPLC-UV analysis	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of a Novel Highly Selective Histamine H4 Receptor Antagonist for the Treatment of Atopic Dermatitis.
AID745773	Half life in mouse liver microsomes	2013	Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11	Bispyrimidines as potent histamine H(4) receptor ligands: delineation of structure-activity relationships and detailed H(4) receptor binding mode.
AID89902	Displacement of [3H]- histamine from the recombinant human histamine H4 receptor	2003	Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19	The first potent and selective non-imidazole human histamine H4 receptor antagonists.
AID256869	In vitro half life in rat liver microsomes	2005	Journal of medicinal chemistry, Dec-29, Volume: 48, Issue:26	Preparation and biological evaluation of indole, benzimidazole, and thienopyrrole piperazine carboxamides: potent human histamine h(4) antagonists.
AID1178165	Agonist activity at human H4R expressed in human U2OS cells assessed as recruitment of beta-arrestin after 2 hrs by PathHunter beta-galactosidase enzyme fragment complementation assay	2014	Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16	Biased ligand modulation of seven transmembrane receptors (7TMRs): functional implications for drug discovery.
AID453002	Inverse agonist activity at human histamine H4 receptor expressed in Sf9 cells co-expressing Galphai2 and Gbeta1gamma2 by [35S]GTPgammaS binding assay relative to maximal inhibition of constitutive response relative to thioperamide	2009	Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20	2,4-Diaminopyrimidines as histamine H4 receptor ligands--Scaffold optimization and pharmacological characterization.
AID390803	Antiinflammatory activity in ip dosed CD1/ICR mouse assessed as reduction of clobenpropit-induced itching	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID386784	Half life in mouse at 5 mg/kg, iv	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID345928	Antagonist activity at human histamine H4 receptor expressed in HEK293 cells coexpressing G-protein assessed as inhibition of histamine-induced intracellular calcium level by FLIPR	2008	Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
AID345932	Displacement of [3H]histamine from human histamine H4 receptor expressed in HEK293 cells by liquid scintillation counting	2008	Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
AID671182	Inhibition of histamine H4 receptor-mediated chemotaxis in mouse bone marrow cells	2012	European journal of medicinal chemistry, Aug, Volume: 54	Detailed structure-activity relationship of indolecarboxamides as H4 receptor ligands.
AID390764	Terminal volume of distribution in mouse at 5 mg/kg, iv	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID390756	Antagonist activity at rat histamine H4 receptor expressed in HEK293 cells coexpressing Gqi5 protein assessed as calcium flux by FLIPR assay	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID638336	Binding affinity to rat histamine H4 receptor	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	Ligand based design of novel histamine H₄ receptor antagonists; fragment optimization and analysis of binding kinetics.
AID1638968	Antagonist activity at histamine H1 receptor in guinea-pig ileum assessed as inhibition of histamine-induced contractions after 15 mins	2019	Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7	Alkyl derivatives of 1,3,5-triazine as histamine H
AID627800	Displacement of [3H]-histamine from guinea pig H4R expressed in HEK293T cells	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
AID627797	Displacement of [3H]-histamine from human H4R expressed in HEK293T cells	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
AID627672	Apparent permeability from apical to basolateral side of human Caco2 cells	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
AID638337	Displacement of [3H]histamine from human H4 receptor expressed in HEK cell membranes	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	Ligand based design of novel histamine H₄ receptor antagonists; fragment optimization and analysis of binding kinetics.
AID1649756	Displacement of [3H]-histamine from human recombinant H4R stably expressed in human SK-N-MC cell membranes
AID256865	Displacement of [3H]histamine from recombinant human histamine H4 receptor in SK-N-MC cells	2005	Journal of medicinal chemistry, Dec-29, Volume: 48, Issue:26	Preparation and biological evaluation of indole, benzimidazole, and thienopyrrole piperazine carboxamides: potent human histamine h(4) antagonists.
AID345930	Antagonist activity at mouse histamine H4 receptor assessed as inhibition of histamine-induced intracellular calcium level by FLIPR	2008	Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
AID345937	Binding affinity to rat histamine H3 receptor	2008	Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
AID386786	AUC (0 to infinity) in mouse at 5 mg/kg, iv	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID391067	Plasma concentration in rat at 100 umol/kg, ip	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID1649746	Inhibition of UR-DEBa242 binding to human recombinant NLuc/GPCR-fused H3R expressed in HEK293T cells measured after 30 mins by furimazine substrate based BRET assay
AID386801	Terminal volume of distribution in mouse at 5 mg/kg, iv	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID1300586	Intrinsic activity at human histamine H3 receptor expressed in sf9 cell membrane co-expressing mammalian Galphai2 and Gbeta1gamma2 at 10 uM incubated for 90 mins by [35S]GTPgammaS binding assay relative to histamine	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.
AID640807	Half life in rat	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Synthesis of novel histamine H4 receptor antagonists.
AID390811	Antiinflammatory activity against carrageenan-induced thermal hyperalgesia in rat assessed as increase in paw withdrawal at 100 umol/kg, ip relative to control	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID627795	Antagonist activity at H4R in human eosinophils assessed as inhibition of histamine-induced actin polymerisation	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
AID630911	Antagonist activity at human histamine H4 receptor by functional assay	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Discovery of a series of potent and selective human H4 antagonists using ligand efficiency and libraries to explore structure-activity relationship (SAR).
AID390807	Agonist activity at rat histamine H4 receptor expressed in HEK293 cells coexpressing Gqi5 protein by GTPgammaS assay	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID386780	Inhibition of CYP2D6 upto 10 uM	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID239984	Binding affinity towards human histamine H4 receptor was determined by [3H]Na-methylhistamine binding to SK-N-MC cell membranes	2004	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21	Synthesis and structure-activity relationships of indole and benzimidazole piperazines as histamine H(4) receptor antagonists.
AID1649753	Displacement of clobenpropit-BODIPY-630/650 from recombinant human NLuc-fused H4R expressed in HEK293T cells by Nano-BRET assay
AID386783	Tmax in mouse at 5 mg/kg, iv	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID1573465	Agonist activity at histamine H4 receptor (unknown origin) assessed as increase in beta-arrestin recruitment relative to control	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID386811	Antinociceptive efficacy in ip dosed rat assessed as inhibition of carrageenan-induced inflammatory pain in paw after 30 mins by hotbox assay	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID390779	Tmax in rat at 10 mg/kg, po	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID671177	Displacement of [3H]histamine from human histamine H4 receptor expressed in HEK cells	2012	European journal of medicinal chemistry, Aug, Volume: 54	Detailed structure-activity relationship of indolecarboxamides as H4 receptor ligands.
AID386791	Half life in mouse at 20 mg/kg, sc	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID386759	Selectivity ratio of Ki for human histamine H4 receptor to Ki for human histamine H3 receptor	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID627677	Oral bioavailability in rat at 10 mg/kg	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
AID386763	Selectivity ratio of Ki for human histamine H4 receptor to Ki for dopamine D2 receptor	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID90041	Binding affinity of compound towards rat histamine H4 receptor	2003	Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19	The first potent and selective non-imidazole human histamine H4 receptor antagonists.
AID1649755	Displacement of [3H]-histamine from human recombinant H4R stably expressed in human SK-N-MC cell homogenates
AID404336	Displacement of [3H]histamine from human histamine H4 receptor expressed in SK-NM-C cells	2008	Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11	Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening.
AID386793	AUC (0 to infinity) in mouse at 20 mg/kg, sc	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID266654	Displacement of [3H]histamine from human histamine H4 receptor transfected in SK-N-MC cells	2006	Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15	Characterization of the histamine H4 receptor binding site. Part 1. Synthesis and pharmacological evaluation of dibenzodiazepine derivatives.
AID1300612	Displacement of [3H]histamine from human histamine H4 receptor expressed in human SK-N-MC cell membrane incubated for 60 mins	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.
AID390806	Antagonist activity at rat histamine H4 receptor expressed in HEK293 cells coexpressing Gqi5 protein by GTPgammaS assay	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID1178164	Antagonist actiivty at human H4R expressed in human U2OS cells assessed as inhibition of [35S]GTPgammaS binding after 30 mins by scintillation proximity assay	2014	Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16	Biased ligand modulation of seven transmembrane receptors (7TMRs): functional implications for drug discovery.
AID239856	pA2 value against histamine h4 receptor	2004	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21	Synthesis and structure-activity relationships of indole and benzimidazole piperazines as histamine H(4) receptor antagonists.
AID386776	Metabolic stability in mouse liver microsomes	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID1649748	Inhibition of UR-DEBa242 binding to mouse recombinant NLuc/GPCR-fused H4R expressed in HEK293T cells measured after 30 mins by furimazine substrate based BRET assay
AID640812	Metabolic stability in rat liver microsomes	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Synthesis of novel histamine H4 receptor antagonists.
AID627674	Metabolic stability in human liver microsomes assessed as half life	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
AID627801	Displacement of [3H]-histamine from rat H4R expressed in HEK293T cells	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
AID390792	Half life in mouse at 20 mg/kg, po	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID1735701	Displacement of [3H]-histamine from recombinant human histamine H4 receptor expressed in CHO-K1 cell membranes measured after 30 mins by microbeta scintillation counting method	2018	Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7	Discovery of a Novel Highly Selective Histamine H4 Receptor Antagonist for the Treatment of Atopic Dermatitis.
AID1272171	Displacement of [3H]histamine from human histamine 4 receptor expressed in HEK293T cell membranes incubated for 1 hr by radioligand binding assay	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.
AID390787	Cmax in rat at 10 mg/kg, po	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID256870	In vitro half life in rat S9 fraction	2005	Journal of medicinal chemistry, Dec-29, Volume: 48, Issue:26	Preparation and biological evaluation of indole, benzimidazole, and thienopyrrole piperazine carboxamides: potent human histamine h(4) antagonists.
AID386779	Inhibition of CYP3A4 upto 10 uM	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID1272172	Binding affinity to histamine 4 receptor (unknown origin)	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.
AID386749	Antagonist activity at human histamine H4 receptor expressed in HEK293 cells assessed as inhibition of histamine-induced intracellular calcium elevation by FLIPR assay	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID345933	Displacement of [3H]histamine from rat histamine H4 receptor expressed in HEK293 cells by liquid scintillation counting	2008	Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
AID386814	Antinociceptive efficacy in ip dosed spinal nerve ligated Sprague-Dawley rat assessed as reduction of neuropathic pain in paw	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID1300577	Intrinsic activity at human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 at 10 uM preincubated for 2 mins followed by [gamma-32P]GTP addition measured after 20 mins by liquid scintillation counting method relative to histamine	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.
AID386792	AUC (0 to t) in mouse at 20 mg/kg, sc	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID386797	Terminal volume of distribution in rat at 10 mg/kg, iv	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID640819	Volume of distribution in rat at 3 mg/kg, sc	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Synthesis of novel histamine H4 receptor antagonists.
AID1300581	Antagonist activity at human histamine H3 receptor expressed in sf9 cell membrane co-expressing mammalian Galphai2 and Gbeta1gamma2 assessed as inhibition of histamine-induced [35S]GTPgammaS binding incubated for 90 mins	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.
AID671181	Inhibition of histamine H4 receptor-mediated chemotaxis in human eosinophils	2012	European journal of medicinal chemistry, Aug, Volume: 54	Detailed structure-activity relationship of indolecarboxamides as H4 receptor ligands.
AID390767	Plasma clearance in rat at 10 mg/kg, iv	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID386787	Terminal volume of distribution in mouse at 5 mg/kg, iv	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID1649759	Displacement of [3H]-histamine from Galphai2/Gbeta1gamma2-coupled human recombinant H4R expressed in baculovirus infected Sf9 insect cell membranes co-expressing RGS19
AID640813	Clearance in rat at 3 mg/kg, sc	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Synthesis of novel histamine H4 receptor antagonists.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346055	Human H4 receptor (Histamine receptors)	2006	Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15	Characterization of the histamine H4 receptor binding site. Part 1. Synthesis and pharmacological evaluation of dibenzodiazepine derivatives.
AID1346055	Human H4 receptor (Histamine receptors)	2004	The Journal of pharmacology and experimental therapeutics, Apr, Volume: 309, Issue:1	A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties.
AID1346055	Human H4 receptor (Histamine receptors)	2005	The Journal of pharmacology and experimental therapeutics, Sep, Volume: 314, Issue:3	Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.
AID1798650	Radioligand Binding Assay from Article 10.1021/jm8007618: \\cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), A New Histamine H4R Antagonist that Blocks Pain Responses against Carrageenan-Induced Hyperalges	2008	Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
AID1798651	Radioligand Binding Assay from Article 10.1021/jm8005959: \\Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.\\	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands.
AID1798682	Radioligand Binding Assay from Article 10.1021/jm800670r: \\Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
AID1798212	Radioligand Binding Assay from Article 10.1124/jpet.103.061754: \\A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties.\\	2004	The Journal of pharmacology and experimental therapeutics, Apr, Volume: 309, Issue:1	A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties.
AID1798265	H4R Radioligand Binding Assay from Article 10.1124/jpet.105.087965: \\Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.\\	2005	The Journal of pharmacology and experimental therapeutics, Sep, Volume: 314, Issue:3	Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.
AID1798266	H3R Radioligand Binding Assay from Article 10.1124/jpet.105.087965: \\Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.\\	2005	The Journal of pharmacology and experimental therapeutics, Sep, Volume: 314, Issue:3	Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (133)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	33 (24.81)	29.6817
2010's	94 (70.68)	24.3611
2020's	6 (4.51)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	24.60 (24.57)
Research Supply Index	4.90 (2.92)
Research Growth Index	4.82 (4.65)
Search Engine Demand Index	29.35 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (24.60)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	7 (5.26%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	126 (94.74%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
gamma-aminobutyric acid gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.	2.04	1	amino acid zwitterion; gamma-amino acid; monocarboxylic acid	human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule
citric acid, anhydrous Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.. citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.	2.11	1	tricarboxylic acid	antimicrobial agent; chelator; food acidity regulator; fundamental metabolite
histamine [no description available]	6.84	46	aralkylamino compound; imidazoles	human metabolite; mouse metabolite; neurotransmitter
melatonin [no description available]	2.04	1	acetamides; tryptamines	anticonvulsant; central nervous system depressant; geroprotector; hormone; human metabolite; immunological adjuvant; mouse metabolite; radical scavenger
croton oil [no description available]	2.07	1	N-acyl-hexosamine
n-methylhistamine [no description available]	2.02	1	aralkylamine
niacinamide nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.	2.11	1	pyridine alkaloid; pyridinecarboxamide; vitamin B3	anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor
niacin Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.. vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).. nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.	3.27	1	pyridine alkaloid; pyridinemonocarboxylic acid; vitamin B3	antidote; antilipemic drug; EC 3.5.1.19 (nicotinamidase) inhibitor; Escherichia coli metabolite; human urinary metabolite; metabolite; mouse metabolite; plant metabolite; vasodilator agent
8-hydroxy-2-(di-n-propylamino)tetralin 8-Hydroxy-2-(di-n-propylamino)tetralin: A serotonin 1A-receptor agonist that is used experimentally to test the effects of serotonin.. 8-OH-DPAT : A tetralin substituted at positions 1 and 7 by hydroxy and dipropylamino groups respectively	2.04	1	phenols; tertiary amino compound; tetralins	serotonergic antagonist
sk&f 82958 [no description available]	3.27	1	benzazepine
4-iodo-2,5-dimethoxyphenylisopropylamine 4-iodo-2,5-dimethoxyphenylisopropylamine: RN given refers to unlabeled parent cpd without isomeric designation; a serotonin agonist. 2-(4-iodo-2,5-dimethoxyphenyl)-1-methylethylamine : An organoiodine compound that is amphetamine bearing two methoxy substituents at positions 2 and 5 as well as an iodo substituent at position 4.	2.04	1	amphetamines; dimethoxybenzene; organoiodine compound
gallopamil Gallopamil: Coronary vasodilator that is an analog of iproveratril (VERAPAMIL) with one more methoxy group on the benzene ring.	2.04	1	benzenes; organic amino compound
octoclothepine octoclothepine: major tranquilizer with action similar to those of the phenothiazines; used in schizophrenic & manic psychoses; minor decriptor (77-86); on-line & INDEX MEDICUS search DIBENZOTHIEPINS (77-86); RN given refers to parent cpd without isomeric designation	2.02	1	dibenzothiepine
sk&f 77434 SK&F 77434: a dopamine D1 receptor partial agonist. N-allyl-1-phenyl-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol : A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a phenyl substituent at position 1, an allyl substituent at position 3 and two hydroxy substituents at positions 7 and 8. Selective dopamine D1-like receptor partial agonist (IC50 values are 19.7 and 2425 nM for binding to D1-like and D2-like receptors respectively). Centrally active following systemic administration in vivo.	3.27	1	benzazepine; catechols; tertiary amino compound	dopamine agonist
sk&f-38393 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine: A selective D1 dopamine receptor agonist used primarily as a research tool.. 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol : A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a phenyl substituent at position 1 and two hydroxy substituents at positions 7 and 8.. SKF 38393 : A racemate comprising equimolar amounts of (R)- and (S)-SKF 38393	3.27	1	benzazepine; catechols; secondary amino compound
1,3-dipropyl-8-cyclopentylxanthine DPCPX : An oxopurine that is 7H-xanthine substituted at positions 1 and 3 by propyl groups and at position 8 by a cyclohexyl group.	2.04	1	oxopurine	adenosine A1 receptor antagonist; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
pk 11195 PK-11195 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 1-(2-chlorophenyl)isoquinoline-3-carboxylic acid with the amino group of sec-butylmethylamine	2.04	1	aromatic amide; isoquinolines; monocarboxylic acid amide; monochlorobenzenes	antineoplastic agent
amoxapine Amoxapine: The N-demethylated derivative of the antipsychotic agent LOXAPINE that works by blocking the reuptake of norepinephrine, serotonin, or both; it also blocks dopamine receptors. Amoxapine is used for the treatment of depression.. amoxapine : A dibenzooxazepine compound having a chloro substituent at the 2-position and a piperazin-1-yl group at the 11-position.	2.02	1	dibenzooxazepine	adrenergic uptake inhibitor; antidepressant; dopaminergic antagonist; geroprotector; serotonin uptake inhibitor
antazoline Antazoline: An antagonist of histamine H1 receptors.. antazoline : A member of the class of imidazolines that is 2-aminomethyl-2-imidazoline in which the exocyclic amino hydrogens are replaced by benzyl and phenyl groups. Antazoline is only found in individuals that have taken the drug.	2.21	1	aromatic amine; imidazolines; tertiary amino compound	cholinergic antagonist; H1-receptor antagonist; xenobiotic
astemizole Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects.. astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position.	2.48	2	benzimidazoles; piperidines	anti-allergic agent; anticoronaviral agent; H1-receptor antagonist
atenolol Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.. atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.	2.04	1	ethanolamines; monocarboxylic acid amide; propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic
betahistine Betahistine: A histamine analog and H1 receptor agonist that serves as a vasodilator. It is used in MENIERE DISEASE and in vascular headaches but may exacerbate bronchial asthma and peptic ulcers.. betahistine : An aminoalkylpyridine that is pyridine substituted by a 2-(methylamino)ethyl group at position 2. It acts as a histamine agonist and a vasodilator, and is thought to improve the microcirculation of the labyrinth, resulting in reduced endolymphatic pressure. It is used (generally as the hydrochloride or mesylate salt) to reduce the symptoms of vertigo, tinnitus, and hearing loss associated with Meniere's disease.	2.07	1	aminoalkylpyridine; secondary amino compound	H1-receptor agonist; vasodilator agent
bethanechol Bethanechol: A slowly hydrolyzing muscarinic agonist with no nicotinic effects. Bethanechol is generally used to increase smooth muscle tone, as in the GI tract following abdominal surgery or in urinary retention in the absence of obstruction. It may cause hypotension, HEART RATE changes, and BRONCHIAL SPASM.. bethanechol : The carbamic acid ester of 2-methylcholine. A slowly hydrolysed muscarinic agonist with no nicotinic effects, it is used as its chloride salt to increase smooth muscle tone, as in the gastrointestinal tract following abdominal surgery, treatment of gastro-oesophageal reflux disease, and as an alternative to catheterisation in the treatment of non-obstructive urinary retention.	2.07	1	carbamate ester; quaternary ammonium ion	muscarinic agonist
carvedilol [no description available]	3.17	1	carbazoles; secondary alcohol; secondary amino compound	alpha-adrenergic antagonist; antihypertensive agent; beta-adrenergic antagonist; cardiovascular drug; vasodilator agent
cetirizine Cetirizine: A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects.. cetirizine : A member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively.	2.75	3	ether; monocarboxylic acid; monochlorobenzenes; piperazines	anti-allergic agent; environmental contaminant; H1-receptor antagonist; xenobiotic
chlorpheniramine Chlorpheniramine: A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than PROMETHAZINE.. chlorphenamine : A tertiary amino compound that is propylamine which is substituted at position 3 by a pyridin-2-yl group and a p-chlorophenyl group and in which the hydrogens attached to the nitrogen are replaced by methyl groups. A histamine H1 antagonist, it is used to relieve the symptoms of hay fever, rhinitis, urticaria, and asthma.	2.11	1	monochlorobenzenes; pyridines; tertiary amino compound	anti-allergic agent; antidepressant; antipruritic drug; H1-receptor antagonist; histamine antagonist; serotonin uptake inhibitor
cimetidine Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.	2.73	3	aliphatic sulfide; guanidines; imidazoles; nitrile	adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
clobenpropit clobenpropit: histamine H3 receptor antagonist. clobenpropit : An imidothiocarbamic ester that consists of isothiourea bearing S-3-(imidazol-4-yl)propyl and N-4-chlorobenzyl substituents. An extremely potent histamine H3 antagonist/inverse agonist (pA2 = 9.93). Also displays partial agonist activity at H4 receptors; induces eosinophil shape change with an EC50 of 3 nM.	3.43	7	imidazoles; imidothiocarbamic ester; organochlorine compound	H3-receptor antagonist; H4-receptor agonist
diazepam Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.	2.51	2	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic
diclofenac Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.	2.04	1	amino acid; aromatic amine; dichlorobenzene; monocarboxylic acid; secondary amino compound	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
dimaprit Dimaprit: A histamine H2 receptor agonist that is often used to study the activity of histamine and its receptors.	2.44	2	imidothiocarbamic ester
diphenhydramine Diphenhydramine: A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.. diphenhydramine : An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug.. antitussive : An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.	2.46	2	ether; tertiary amino compound	anti-allergic agent; antidyskinesia agent; antiemetic; antiparkinson drug; antipruritic drug; antitussive; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; oneirogen; sedative
ebastine [no description available]	2.02	1	organic molecular entity
fenoldopam Fenoldopam: A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.	3.27	1	benzazepine	alpha-adrenergic agonist; antihypertensive agent; dopamine agonist; dopaminergic antagonist; vasodilator agent
fentanyl Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078). fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.	3.27	1	anilide; monocarboxylic acid amide; piperidines	adjuvant; anaesthesia adjuvant; anaesthetic; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
fexofenadine fexofenadine: a second generation antihistamine; metabolite of the antihistaminic drug terfenadine; structure in first source; RN refers to HCl. fexofenadine : A piperidine-based anti-histamine compound.	2.02	1	piperidines; tertiary amine	anti-allergic agent; H1-receptor antagonist
gabapentin Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.. gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.	2.04	1	gamma-amino acid	anticonvulsant; calcium channel blocker; environmental contaminant; xenobiotic
haloperidol Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.	2.04	1	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
alpha-methylhistamine alpha-methylhistamine: a histamine H3 receptor agonist; RN given refers to parent cpd without isomeric designation. alpha-methylhistamine : An aralkylamino compound that is histamine bearing a methyl substituent at the alpha-position.	2.04	1	aralkylamino compound; imidazoles	animal metabolite; H3-receptor agonist
hydroxyzine Hydroxyzine: A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.. hydroxyzine : A N-alkylpiperazine that is piperzine in which the nitrogens atoms are substituted by 2-(2-hydroxyethoxy)ethyl and (4-chlorophenyl)(phenyl)methyl groups respectively.	2.44	2	hydroxyether; monochlorobenzenes; N-alkylpiperazine	anticoronaviral agent; antipruritic drug; anxiolytic drug; dermatologic drug; H1-receptor antagonist
ici 118551 [no description available]	2.04	1	indanes
imetit imetit: structure given in first source. imetit : An imidothiocarbamic ester that consists of isothiourea in which the thiol hydrogen is substituted by a 2-(imidazol-4-yl)ethyl group. An extremely potent, high affinity agonist at H3 and H4 receptors (Ki values are 0.3 and 2.7 nM respectively). Induces shape change in eosinophils with an EC50 of 25 nM. Centrally active following systemic administration.	2.73	3	imidazoles; imidothiocarbamic ester	H3-receptor agonist; H4-receptor agonist
imipramine Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.. imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.	2.04	1	dibenzoazepine	adrenergic uptake inhibitor; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	2.46	2	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
ketanserin Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.. ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.	2.04	1	aromatic ketone; organofluorine compound; piperidines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; cardiovascular drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist
ketotifen Ketotifen: A cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators. It has been proposed for the treatment of asthma, rhinitis, skin allergies, and anaphylaxis.. ketotifen : An organic heterotricyclic compound that is 4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one which is substituted at position 4 by a 1-methylpiperidin-4-ylidene group. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is used (usually as its hydrogen fumarate salt) for the treatment of asthma, where it may take several weeks to exert its full effect.	2.05	1	cyclic ketone; olefinic compound; organic heterotricyclic compound; organosulfur heterocyclic compound; piperidines; tertiary amino compound	anti-asthmatic drug; H1-receptor antagonist
loratadine Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.. loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.	2.44	2	benzocycloheptapyridine; ethyl ester; N-acylpiperidine; organochlorine compound; tertiary carboxamide	anti-allergic agent; cholinergic antagonist; geroprotector; H1-receptor antagonist
loxapine Loxapine: An antipsychotic agent used in SCHIZOPHRENIA.	2.43	2	dibenzooxazepine	antipsychotic agent; dopaminergic antagonist
meclizine Meclizine: A histamine H1 antagonist used in the treatment of motion sickness, vertigo, and nausea during pregnancy and radiation sickness.	2.31	1	diarylmethane
methoctramine [no description available]	2.04	1	aromatic ether; tetramine	muscarinic antagonist
pirenzepine Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.	2.04	1	pyridobenzodiazepine	anti-ulcer drug; antispasmodic drug; muscarinic antagonist
prazosin Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.. prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.	2.04	1	aromatic ether; furans; monocarboxylic acid amide; piperazines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
protriptyline Protriptyline: Tricyclic antidepressant similar in action and side effects to IMIPRAMINE. It may produce excitation.	2.04	1	carbotricyclic compound	antidepressant
pyrilamine Pyrilamine: A histamine H1 antagonist. It has mild hypnotic properties and some local anesthetic action and is used for allergies (including skin eruptions) both parenterally and locally. It is a common ingredient of cold remedies.. mepyramine : An ethylenediamine derivative that is ethylenediamine in which one of the amino nitrogens is substituted by two methyl groups and the remaining amino nitrogen is substituted by a 4-methoxybenzyl and a pyridin-2-yl group.	3.45	7	aromatic ether; ethylenediamine derivative	H1-receptor antagonist
n-methylquipazine N-methylquipazine: structure in first source. N-methylquipazine : An aminoquinoline that consists of quinoline in which the hydrogen at position 2 is substituted by a 4-methylpiperazin-1-yl group. A 5-HT3 agonist. Has almost the same affinity for 5-HT3 sites as quipazine but unlike the latter, does not bind to 5-HT1B sites.	2.04	1	aminoquinoline; N-alkylpiperazine; N-arylpiperazine	serotonergic agonist
corticosterone [no description available]	2.11	1	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
methacholine chloride Methacholine Chloride: A quaternary ammonium parasympathomimetic agent with the muscarinic actions of ACETYLCHOLINE. It is hydrolyzed by ACETYLCHOLINESTERASE at a considerably slower rate than ACETYLCHOLINE and is more resistant to hydrolysis by nonspecific CHOLINESTERASES so that its actions are more prolonged. It is used as a parasympathomimetic bronchoconstrictor agent and as a diagnostic aid for bronchial asthma. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1116)	2.13	1	quaternary ammonium salt
phenylalanine Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.	2.04	1	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; phenylalanine; proteinogenic amino acid	algal metabolite; EC 3.1.3.1 (alkaline phosphatase) inhibitor; Escherichia coli metabolite; human xenobiotic metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
cycloheximide Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.	2.08	1	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor
dinitrofluorobenzene Dinitrofluorobenzene: Irritants and reagents for labeling terminal amino acid groups.. 1-fluoro-2,4-dinitrobenzene : The organofluorine compound that is benzene with a fluoro substituent at the 1-position and two nitro substituents in the 2- and 4-positions.	2.17	1	C-nitro compound; organofluorine compound	agrochemical; allergen; chromatographic reagent; EC 2.7.3.2 (creatine kinase) inhibitor; protein-sequencing agent; spectrophotometric reagent
veratridine [no description available]	2.04	1	steroid	sodium channel modulator
rotenone Derris: A plant genus of the family FABACEAE. The root is a source of rotenoids (ROTENONE) and flavonoids. Some species of Pongamia have been reclassified to this genus and some to MILLETTIA. Some species of Deguelia have been reclassified to this genus.. rotenoid : Members of the class of tetrahydrochromenochromene that consists of a cis-fused tetrahydrochromeno[3,4-b]chromene skeleton and its substituted derivatives. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds.	2.21	1	organic heteropentacyclic compound; rotenones	antineoplastic agent; metabolite; mitochondrial NADH:ubiquinone reductase inhibitor; phytogenic insecticide; piscicide; toxin
picryl chloride Picryl Chloride: A hapten that generates suppressor cells capable of down-regulating the efferent phase of trinitrophenol-specific contact hypersensitivity. (Arthritis Rheum 1991 Feb;34(2):180).. 1-chloro-2,4,6-trinitrobenzene : The C-nitro compound that is chlorobenzene with three nitro substituents in the 2-, 4- and 6-positions.	2.76	3	C-nitro compound; monochlorobenzenes	allergen; epitope; explosive; hapten
ergotamine Ergotamine: A vasoconstrictor found in ergot of Central Europe. It is a serotonin agonist that has been used as an oxytocic agent and in the treatment of MIGRAINE DISORDERS.. ergotamine : A peptide ergot alkaloid that is dihydroergotamine in which a double bond replaces the single bond between positions 9 and 10.	3.27	1	peptide ergot alkaloid	alpha-adrenergic agonist; mycotoxin; non-narcotic analgesic; oxytocic; serotonergic agonist; vasoconstrictor agent
yohimbine Yohimbine: A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of ERECTILE DYSFUNCTION.. yohimbine : An indole alkaloid with alpha2-adrenoceptor antagonist activity. It is produced by Corynanthe johimbe and Rauwolfia serpentina.	2.04	1	methyl 17-hydroxy-20xi-yohimban-16-carboxylate	alpha-adrenergic antagonist; dopamine receptor D2 antagonist; serotonergic antagonist
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	2.13	1	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
thiazoles [no description available]	2.07	1	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
trinitrobenzenesulfonic acid Trinitrobenzenesulfonic Acid: A reagent that is used to neutralize peptide terminal amino groups.. 2,4,6-trinitrobenzenesulfonic acid : The arenesulfonic acid that is benzenesulfonic acid with three nitro substituents in the 2-, 4- and 6-positions.	2.46	2	arenesulfonic acid; C-nitro compound	epitope; explosive; reagent
toluene 2,4-diisocyanate Toluene 2,4-Diisocyanate: Skin irritant and allergen used in the manufacture of polyurethane foams and other elastomers.. toluene 2,4-diisocyanate : A toluene meta-diisocyanate in which the isocyanato groups are at positions 2 and 4 relative to the methyl group on the benzene ring.	2.13	1	toluene meta-diisocyanate	allergen; hapten
dronabinol Dronabinol: A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound.. Delta(9)-tetrahydrocannabinol : A diterpenoid that is 6a,7,8,10a-tetrahydro-6H-benzo[c]chromene substituted at position 1 by a hydroxy group, positions 6, 6 and 9 by methyl groups and at position 3 by a pentyl group. The principal psychoactive constituent of the cannabis plant, it is used for treatment of anorexia associated with AIDS as well as nausea and vomiting associated with cancer chemotherapy.	3.27	1	benzochromene; diterpenoid; phytocannabinoid; polyketide	cannabinoid receptor agonist; epitope; hallucinogen; metabolite; non-narcotic analgesic
perlapine perlapine: structure; RN given refers to parent cpd	2.03	1	organic molecular entity
fluorescein-5-isothiocyanate Fluorescein-5-isothiocyanate: Fluorescent probe capable of being conjugated to tissue and proteins. It is used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.. fluorescein 5-isothiocyanate : The 5-isomer of fluorescein isothiocyanate. Acts as a fluorescent probe capable of being conjugated to tissue and proteins; used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.	2.05	1	fluorescein isothiocyanate
azatadine azatadine: indulian (UD 21;71k) is dimaleate; do not confuse with AZACITIDINE. azatadine : A benzo[5,6]cyclohepta[1,2-b]pyridine having a 1-methylpiperidin-4-ylidene group at the 11-position.	2.02	1	benzocycloheptapyridine; tertiary amine	anti-allergic agent; H1-receptor antagonist
dimethindene Dimethindene: A histamine H1 antagonist. It is used in hypersensitivity reactions, in rhinitis, for pruritus, and in some common cold remedies.	2.11	1	indene
n-methylaspartate N-Methylaspartate: An amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors (RECEPTORS, NMDA).. N-methyl-D-aspartic acid : An aspartic acid derivative having an N-methyl substituent and D-configuration.	2.15	1	amino dicarboxylic acid; D-alpha-amino acid; D-aspartic acid derivative; secondary amino compound	neurotransmitter agent
triamcinolone Triamcinolone: A glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. (From Martindale, The Extra Pharmacopoeia, 30th ed, p739). triamcinolone : A C21-steroid hormone that is 1,4-pregnadiene-3,20-dione carrying four hydroxy substituents at positions 11beta, 16alpha, 17alpha and 21 as well as a fluoro substituent at position 9. Used in the form of its 16,17-acetonide to treat various skin infections.	2.06	1	11beta-hydroxy steroid; 16alpha-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-allergic agent; anti-inflammatory drug
isothiuronium Isothiuronium: An undecenyl THIOUREA which may have topical anti-inflammatory activity.	2.02	1
1-(3-chloro-5-benzo[b][1]benzoxepinyl)-4-methylpiperazine [no description available]	2.03	1	N-alkylpiperazine; organic heterotricyclic compound
glutamic acid Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.	3.27	1	glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical
substance p [no description available]	2.05	1	peptide	neurokinin-1 receptor agonist; neurotransmitter; vasodilator agent
butaclamol [no description available]	2.04	1	amino alcohol; organic heteropentacyclic compound; tertiary alcohol; tertiary amino compound	dopaminergic antagonist
4-methylhistamine 4-methylhistamine: RN given refers to parent cpd. 4-methylhistamine : An aralkylamino compound that is histamine bearing a methyl substituent at the 5 position on the ring.	4.03	13	aralkylamino compound; imidazoles	histamine agonist; metabolite
quisqualic acid Quisqualic Acid: An agonist at two subsets of excitatory amino acid receptors, ionotropic receptors that directly control membrane channels and metabotropic receptors that indirectly mediate calcium mobilization from intracellular stores. The compound is obtained from the seeds and fruit of Quisqualis chinensis.	3.27	1	non-proteinogenic alpha-amino acid
impromidine Impromidine: A highly potent and specific histamine H2 receptor agonist. It has been used diagnostically as a gastric secretion indicator.	2.42	2
sufentanil Sufentanil: An opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent.. sufentanil : An anilide resulting from the formal condensation of the aryl amino group of 4-(methoxymethyl)-N-phenyl-1-[2-(2-thienyl)ethyl]piperidin-4-amine with propanoic acid.	3.27	1	anilide; ether; piperidines; thiophenes	anaesthesia adjuvant; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
tiotidine tiotidine: UD gives slightly different structure for this cpd; RN given refers to parent cpd; structure in first source	2.02	1	thiazoles
aripiprazole Aripiprazole: A piperazine and quinolone derivative that is used primarily as an antipsychotic agent. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A. It is used for the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER, and as an adjunct therapy for the treatment of depression.. aripiprazole : An N-arylpiperazine that is piperazine substituted by a 4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl group at position 1 and by a 2,3-dichlorophenyl group at position 4. It is an antipsychotic drug used for the treatment of Schizophrenia, and other mood disorders.	3.27	1	aromatic ether; delta-lactam; dichlorobenzene; N-alkylpiperazine; N-arylpiperazine; quinolone	drug metabolite; H1-receptor antagonist; second generation antipsychotic; serotonergic agonist
mizolastine [no description available]	2.02	1	benzimidazoles
mifentidine [no description available]	2.02	1
2-(2-aminoethyl)pyridine 2-(2-aminoethyl)pyridine: histamine H1 receptor agonist inducing cross-tolerance to histamine; RN given refers to parent cpd; structure	2.02	1	aminoalkylpyridine; primary amine	histamine agonist; metabolite
2-(2-aminoethyl)thiazole 2-(2-aminoethyl)thiazole: receptor H1 agonist; RN given refers to parent cpd	2.02	1	1,3-thiazoles
fibrinogen Fibrinogen: Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.. D-iditol : The D-enantiomer of iditol.	2.1	1	iditol	fungal metabolite
alpha,beta-methyleneadenosine 5'-triphosphate alpha,beta-methyleneadenosine 5'-triphosphate: do not confuse with beta,gamma-methylene ATP; RN given refers to parent cpd	2.04	1	nucleoside triphosphate analogue
2-methylhistamine 2-methylhistamine: RN given refers to parent cpd. 2-methylhistamine : An aralkylamino compound that is histamine bearing a methyl substituent at the 2 position on the ring.	2.02	1	aralkylamino compound; imidazoles	histamine agonist; metabolite
glycidyl nitrate glycidyl nitrate: a nitric oxide donor; structure in first source. peptidoglycan : A peptidoglycosaminoglycan formed by alternating residues of beta-(1->4)-linked N-acetylglucosamine and N-acetylmuramic acid {2-amino-3-O-[(S)-1-carboxyethyl]-2-deoxy-D-glucose} residues. Attached to the carboxy group of the muramic acid is a peptide chain of three to five amino acids.	2.51	2
phenylisopropyladenosine [no description available]	3.27	1	aromatic amine; benzenes; hydrocarbyladenosine; purine nucleoside; secondary amino compound	adenosine A1 receptor agonist; neuroprotective agent
p-methoxy-n-methylphenethylamine p-Methoxy-N-methylphenethylamine: A potent mast cell degranulator. It is involved in histamine release.. N,O-dimethyltyramine : A secondary amino compound that is tyramine in which the hydrogen of the phenolic hydroxy group has been replaced by a methyl group.	2.05	1	aromatic ether; secondary amino compound	metabolite
u 73122 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione: structure given in first source. U-73122 : An aza-steroid that is 3-O-methyl-17beta-estradiol in which the 17beta-hydroxy group is replaced by a 6-(maleimid-1-yl)hexylamino group. An inibitor of phospholipase C.	2.11	1	aromatic ether; aza-steroid; maleimides	EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor
sr141716 [no description available]	3.27	1	amidopiperidine; carbohydrazide; dichlorobenzene; monochlorobenzenes; pyrazoles	anti-obesity agent; appetite depressant; CB1 receptor antagonist
bosentan anhydrous Bosentan: A sulfonamide and pyrimidine derivative that acts as a dual endothelin receptor antagonist used to manage PULMONARY HYPERTENSION and SYSTEMIC SCLEROSIS.	3.27	1	primary alcohol; pyrimidines; sulfonamide	antihypertensive agent; endothelin receptor antagonist
cp-55,940 [no description available]	3.59	2
u 69593 U 69593: selective ligand for opioid K-receptor. U69593 : A monocarboxylic acid amide obtained by formal condensation between the carboxy group of phenylacetic acid and the secodary amino group of (5R,7S,8S)-N-methyl-7-(pyrrolidin-1-yl)-1-oxaspiro[4.5]decan-8-amine.	3.27	1	monocarboxylic acid amide; N-alkylpyrrolidine; organic heterobicyclic compound; oxaspiro compound	anti-inflammatory agent; diuretic; kappa-opioid receptor agonist
n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine: structure given in first source; a selective A(3) adenosine receptor agonist. 3-iodobenzyl-5'-N-methylcarboxamidoadenosine : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by N-ethylcarboxamido and one of the hydrogens of the exocyclic amino function is substituted by a 3-iodobenzyl group.	3.59	2	adenosines; monocarboxylic acid amide; organoiodine compound	adenosine A3 receptor agonist
1-(1-(2-benzo(b)thienyl)cyclohexyl)piperidine 1-(1-(2-benzo(b)thienyl)cyclohexyl)piperidine: structure given in first source. 1-[1-(1-benzothiophen-2-yl)cyclohexyl]piperidine : A tertiary amino compound that consists of cyclohexane having piperidin-1-yl and benzothiophen-2-yl groups attached at position 1. A potent dopamine re-uptake inhibitor with a behavioral profile different from that of phencyclidine (PCP) and similar to that of cocaine.	2.04	1	1-benzothiophenes; piperidines; tertiary amino compound	dopamine uptake inhibitor
amthamine amthamine: histamine H2 receptor agonist; structure & RN given in first source; RN given refers to parent cpd	2.45	2	thiazoles
salvinorin a salvinorin A: from the herb, Salvia divinorum	3.27	1	organic heterotricyclic compound; organooxygen compound	metabolite; oneirogen
iodoproxyfan iodoproxyfan: structure given in first source	2.44	2
sk&f 83959 SK&F 83959: induces grooming & vacuous chewing; agonist of dopamine D1-like receptors that inhibits dopamine sensitive adenylyl cyclase. N-methyl-6-chloro-1-(3-methylphenyl)-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol : A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a 3-methylphenyl substituent at position 1, a methyl substituent at position 3, a chloro substituent at position 6 and two hydroxy substituents at positions 7 and 8. Dopamine D1-like receptor partial agonist (Ki values are 1.18, 7.56, 920 and 399 nM for rat D1, D5, D2 and D3 receptors respectively). May act as an antagonist in vivo, producing anti-Parkinsonian effects and antagonising the behavioral effects of cocaine.	3.27	1	benzazepine; catechols; organochlorine compound; tertiary amino compound	dopamine agonist
naproxen Naproxen: An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.. naproxen : A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.	2.1	1	methoxynaphthalene; monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
alpha-methylhistamine (R)-alpha-methylhistamine : An aralkylamino compound that is histamine bearing a methyl substituent at the alpha-position (the R-enantiomer).	2.72	3	aralkylamino compound; imidazoles	H3-receptor agonist
aminopotentidine aminopotentidine: structure given in first source; RN given refers to the oxalate. aminopotentidine : A benzamide obtained by formal condensation of the carboxy group of 4-aminobenzoic acid with the primary amino group of 1-(2-aminoethyl)-2-cyano-3-{3-[3-(piperidin-1-ylmethyl)phenoxy]propyl}guanidine.	2.02	1	aromatic ether; benzamides; guanidines; nitrile; piperidines; substituted aniline	H2-receptor antagonist
imidazolyl-4-propylamine imidazolyl-4-propylamine: structure given in first source	2.02	1
sk&f 75670 [no description available]	3.27	1
atropine tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3.	2.21	1
dizocilpine [no description available]	2.04	1	secondary amino compound; tetracyclic antidepressant	anaesthetic; anticonvulsant; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist
2'-deoxyadenosine 5'-o-(1-thiotriphosphate) 2'-deoxyadenosine 5'-O-(1-thiotriphosphate): RN given refers to cpd without isomeric designation; structure.	2.04	1
picrotoxinin [no description available]	2.04	1	epoxide; gamma-lactone; organic heteropentacyclic compound; picrotoxane sesquiterpenoid; tertiary alcohol	GABA antagonist; plant metabolite; serotonergic antagonist
n-formylmethionine leucyl-phenylalanine N-Formylmethionine Leucyl-Phenylalanine: A formylated tripeptide originally isolated from bacterial filtrates that is positively chemotactic to polymorphonuclear leucocytes, and causes them to release lysosomal enzymes and become metabolically activated.. N-formyl-L-methionyl-L-leucyl-L-phenylalanine : A tripeptide composed of L-Met, L-Leu and L-Phe in a linear sequence with a formyl group at the amino terminus. It acts as a potent inducer of leucocyte chemotaxis and macrophage activator as well as a ligand for the FPR receptor.	2.79	3	tripeptide
adenosine-5'-(n-ethylcarboxamide) Adenosine-5'-(N-ethylcarboxamide): A stable adenosine A1 and A2 receptor agonist. Experimentally, it inhibits cAMP and cGMP phosphodiesterase activity.. N-ethyl-5'-carboxamidoadenosine : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by an N-ethylcarboxamido group.	2.04	1	adenosines; monocarboxylic acid amide	adenosine A1 receptor agonist; adenosine A2A receptor agonist; antineoplastic agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
bemesetron [no description available]	2.04	1
levocetirizine [no description available]	2.1	1	diarylmethane
thiourea Thiourea: A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS.. thiourea : The simplest member of the thiourea class, consisting of urea with the oxygen atom substituted by sulfur.	3.3	6	one-carbon compound; thioureas; ureas	antioxidant; chromophore
ranitidine Ranitidine: A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers.. ranitidine : A member of the class of furans used to treat peptic ulcer disease (PUD) and gastroesophageal reflux disease.	3.16	5	C-nitro compound; furans; organic sulfide; tertiary amino compound	anti-ulcer drug; drug allergen; environmental contaminant; H2-receptor antagonist; xenobiotic
4-diphenylacetoxy-n-methylpiperidine methiodide 4-DAMP methiodide : A quaternary ammonium salt obtained by combining equimolar amounts of 4-diphenylacetoxy-N-methylpiperidine and iodomethane.	2.04	1	iodide salt; quaternary ammonium salt	cholinergic antagonist; muscarinic antagonist
burimamide Burimamide: An antagonist of histamine that appears to block both H2 and H3 histamine receptors. It has been used in the treatment of ulcers.	2.42	2	imidazoles
triptorelin iodophenpropit: structure given in first source	2.97	4	organoiodine compound
4-(1h-imidazol-4-ylmethyl)piperidine 4-(1H-imidazol-4-ylmethyl)piperidine: structure in first source	2.74	3	piperidines
thioperamide thioperamide: structure given in first source; histamine H3 receptor antagonist	9.14	15	primary aliphatic amine
u-50488 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer: A non-peptide, kappa-opioid receptor agonist which has also been found to stimulate the release of adrenocorticotropin (ADRENOCORTICOTROPIC HORMONE) via the release of hypothalamic arginine vasopressin (ARGININE VASOPRESSIN) and CORTICOTROPIN-RELEASING HORMONE. (From J Pharmacol Exp Ther 1997;280(1):416-21). U50488 : A monocarboxylic acid amide obtained by formal condensation between the carboxy group of 3,4-dichlorophenylacetic acid and the secondary amino group of (1R,2R)-N-methyl-2-(pyrrolidin-1-yl)cyclohexanamine	2.04	1	dichlorobenzene; monocarboxylic acid amide; N-alkylpyrrolidine	analgesic; antitussive; calcium channel blocker; diuretic; kappa-opioid receptor agonist
sch 23390 SCH 23390: a selective D1-receptor antagonist. SCH 23390 : A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a phenyl substituent at position 1, a methyl substituent at position 3, a chloro substituent at position 7 and a hydroxy substituent at position 8.	2.04	1	benzazepine
vuf 8430 S-(2-guanidylethyl)isothiourea: a histamine H4 receptor agonist; structure in first source	3.15	5
ovalbumin Ovalbumin: An albumin obtained from the white of eggs. It is a member of the serpin superfamily.	3.58	8
rs 102221 [no description available]	2.04	1	aromatic ketone
jhw 015 [no description available]	3.27	1	indolecarboxamide
am 630 iodopravadoline: an aminoalkylindole; a competitive cannabinoid receptor antagonist; structure given in first source	3.27	1	N-acylindole
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	2.04	1	prostaglandins E	human metabolite; mouse metabolite; oxytocic
11-cis-retinal Rhodopsin: A purplish-red, light-sensitive pigment found in RETINAL ROD CELLS of most vertebrates. It is a complex consisting of a molecule of ROD OPSIN and a molecule of 11-cis retinal (RETINALDEHYDE). Rhodopsin exhibits peak absorption wavelength at about 500 nm.. 11-cis-retinal : A retinal having 2E,4Z,6E,8E-double bond geometry.	2.04	1	retinal	chromophore; human metabolite; mouse metabolite
olopatadine hydrochloride Olopatadine Hydrochloride: An antihistamine with mast-cell stabilizing properties used as eye drops in the treatment of ALLERGIC CONJUNCTIVITIS.	2.48	2	dibenzooxazepine
granisetron Granisetron: A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic for cancer chemotherapy patients.. granisetron : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of 1-methyl-1H-indazole-3-carboxylic acid with the primary amino group of (3-endo)-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine. A selective 5-HT3 receptor antagonist, it is used (generally as the monohydrochloride salt) to manage nausea and vomiting caused by cancer chemotherapy and radiotherapy, and to prevent and treat postoperative nausea and vomiting.	2.17	1	aromatic amide; indazoles
2-(3-trifluoromethylphenyl)histamine 2-(3-trifluoromethylphenyl)histamine: a selective histamine H1-receptor agonist	2.07	1
iloprost Iloprost: An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation.. iloprost : A carbobicyclic compound that is prostaglandin I2 in which the endocyclic oxygen is replaced by a methylene group and in which the (1E,3S)-3-hydroxyoct-1-en-1-yl side chain is replaced by a (3R)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl group. A synthetic analogue of prostacyclin, it is used as the trometamol salt (generally by intravenous infusion) for the treatment of peripheral vascular disease and pulmonary hypertension.	2.04	1	carbobicyclic compound; monocarboxylic acid; secondary alcohol	platelet aggregation inhibitor; vasodilator agent
j 113397 J 113397: an opioid receptor-like 1 (ORL1), orphanin FQ, and nociceptin receptor antagonist; structure in first source	3.27	1
cytochalasin b Cytochalasin B: A cytotoxic member of the CYTOCHALASINS.. cytochalasin B : An organic heterotricyclic compound, that is a mycotoxin which is cell permeable an an inhibitor of cytoplasmic division by blocking the formation of contractile microfilaments.	2.1	1	cytochalasin; lactam; lactone; organic heterotricyclic compound	actin polymerisation inhibitor; metabolite; mycotoxin; platelet aggregation inhibitor
(3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone WIN 55212-2 : A organic heterotricyclic compound that is 5-methyl-3-(morpholin-4-ylmethyl)-2,3-dihydro[1,4]oxazino[2,3,4-hi]indole substituted at position 6 by a 1-naphthylcarbonyl group.	3.27	1	morpholines; naphthyl ketone; organic heterotricyclic compound; synthetic cannabinoid	analgesic; apoptosis inhibitor; neuroprotective agent
enkephalin, ala(2)-mephe(4)-gly(5)- [no description available]	2.04	1	peptide
famotidine [no description available]	2.02	1	1,3-thiazoles; guanidines; sulfonamide	anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
mastoparan [no description available]	2.05	1	mastoparans; peptidyl amide	antimicrobial agent
saralasin Saralasin: An octapeptide analog of angiotensin II (bovine) with amino acids 1 and 8 replaced with sarcosine and alanine, respectively. It is a highly specific competitive inhibitor of angiotensin II that is used in the diagnosis of HYPERTENSION.	2.04	1	oligopeptide
dizocilpine maleate Dizocilpine Maleate: A potent noncompetitive antagonist of the NMDA receptor (RECEPTORS, N-METHYL-D-ASPARTATE) used mainly as a research tool. The drug has been considered for the wide variety of neurodegenerative conditions or disorders in which NMDA receptors may play an important role. Its use has been primarily limited to animal and tissue experiments because of its psychotropic effects.. dizocilpine maleate : A maleate salt obtained by reaction of dizocilpine with one equivalent of maleic acid.	2.15	1	maleate salt; tetracyclic antidepressant	anaesthetic; anticonvulsant; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist
proxyfan [no description available]	2.02	1	benzyl ether
ciproxifan [no description available]	2.08	1	aromatic ketone
1-palmitoyl-2-oleoylphosphatidylcholine 1-palmitoyl-2-oleoylphosphatidylcholine: RN given refers to (Z)-isomer	2.04	1
involucrin involucrin: soluble precursor protein of cross-linked envelope characteristic of epidermal s. corneum synthesized by keratinocytes in natural & cultured human epithelia; see also related records for prekeratin & stratum corneum basic protein precursor	2.1	1
trk 820 TRK 820: structure in first source	3.27	1	phenanthrenes
(2S)-1-(1H-imidazol-5-yl)-2-propanamine [no description available]	2.02	1	aralkylamine
sb 222200 [no description available]	2.04	1	quinolines
impentamine impentamine: structure in first source	2.02	1
dibutyl phthalate 6-((3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-N-methyl-3-pyridinecarboxamide: GSK-189254 is the HCl salt; an H3 receptor antagonist; putative cognitive enhancer; structure in first source	2.11	1
sincalide Sincalide: An octapeptide hormone present in the intestine and brain. When secreted from the gastric mucosa, it stimulates the release of bile from the gallbladder and digestive enzymes from the pancreas.	2.04	1	oligopeptide
mocetinostat mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).	2.46	2	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent
6'-guanidinonaltrindole 6'-guanidinonaltrindole: a tissue-selective analgesic; structure in first source	3.27	1
4-(1H-imidazol-5-ylmethyl)pyridine [no description available]	2.02	1	pyridines
alpha-synuclein alpha-Synuclein: A synuclein that is a major component of LEWY BODIES and plays a role in SYNUCLEINOPATHIES, neurodegeneration and neuroprotection.	2.21	1
jnj 10191584 JNJ 10191584: histamine H4 receptor antagonist	5.23	15	benzimidazoles
histaprodifen [no description available]	2.02	1
6,7-dichloro 3-(4-methylpiperazin-1-yl)quinoxalin-2(1h)-one 6,7-dichloro 3-(4-methylpiperazin-1-yl)quinoxalin-2(1H)-one: an NSAID; structure in first source	4.08	4
methimepip methimepip: histamine H3 agonist	2.02	1
4-(1h-imidazol-4-yl)butanamine 4-(1H-imidazol-4-yl)butanamine: agonist of both H3 and H4 histamine receptors; structure in first source	2.46	2
somatostatin [no description available]	2.04	1	heterodetic cyclic peptide; peptide hormone
nociceptin [no description available]	2.04	1	organic molecular entity; polypeptide	human metabolite; rat metabolite
neuropeptide y Neuropeptide Y: A 36-amino acid peptide present in many organs and in many sympathetic noradrenergic neurons. It has vasoconstrictor and natriuretic activity and regulates local blood flow, glandular secretion, and smooth muscle activity. The peptide also stimulates feeding and drinking behavior and influences secretion of pituitary hormones.	2.04	1
glucagon-like peptide 1 Glucagon-Like Peptide 1: A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.	3.27	1
msh, 4-nle-7-phe-alpha- [no description available]	2.04	1	polypeptide	dermatologic drug
bombesin [no description available]	2.04	1
endothelin-1 Endothelin-1: A 21-amino acid peptide produced in a variety of tissues including endothelial and vascular smooth-muscle cells, neurons and astrocytes in the central nervous system, and endometrial cells. It acts as a modulator of vasomotor tone, cell proliferation, and hormone production. (N Eng J Med 1995;333(6):356-63)	3.27	1
phosphatidylcholines Phosphatidylcholines: Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety.	2.04	1	1,2-diacyl-sn-glycero-3-phosphocholine
vuf10166 [no description available]	2.04	1
pf-3893787 PF-3893787: structure in first source	3.87	3
neurotensin neurotensin, Tyr(11)-: RN given refers to parent cpd & (D)-isomer; RN for cpd without isomeric designation not avail 5/91	2.04	1	peptide hormone	human metabolite; mitogen; neurotransmitter; vulnerary
piperidines Piperidines: A family of hexahydropyridines.	3.46	7
endothelins [no description available]	2.04	1
interleukin-8 Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.	2.1	1
pituitary adenylate cyclase activating polypeptide 38 [no description available]	2.04	1
2-[5-[(3,4-dichlorophenyl)methylthio]-4-(2-furanylmethyl)-1,2,4-triazol-3-yl]pyridine [no description available]	3.27	1	triazoles
ur-144 (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone: structure in first source	3.27	1
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	2.52	2
trp-lys-tyr-met-val-met Trp-Lys-Tyr-Met-Val-Met: a synthetic peptide, stimulates phosphoinositide hyrolysis in human leukocytes	3.27	1
22-thiocyanatosalvinorin a 22-thiocyanatosalvinorin A: structure in first source	3.27	1
deoxyguanosine [no description available]	2.1	1	purine 2'-deoxyribonucleoside; purines 2'-deoxy-D-ribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
clozapine Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.	2.95	4	benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound	adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic
8-hydroxy-2'-deoxyguanosine 8-Hydroxy-2'-Deoxyguanosine: Common oxidized form of deoxyguanosine in which C-8 position of guanine base has a carbonyl group.. 8-hydroxy-2'-deoxyguanosine : Guanosine substituted at the purine 8-position by a hydroxy group. It is used as a biomarker of oxidative DNA damage.	2.1	1	guanosines	biomarker

Condition	Relationship Strength	Studies
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	6.29	33
Innate Inflammatory Response [description not available]	5.81	20
Ache [description not available]	2.96	4
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	5.81	20
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	2.96	4
Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.	2.76	3
Allodynia [description not available]	2.73	3
Primary Peritonitis [description not available]	2.04	1
Peritonitis INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.	2.04	1
Allergic Reaction [description not available]	3.92	4
Hypersensitivity Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.	3.92	4
Polyarthritis [description not available]	2.1	1
Itching [description not available]	4.78	11
Arthritis Acute or chronic inflammation of JOINTS.	2.1	1
Pruritus An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.	4.78	11
Rheumatoid Arthritis [description not available]	3.42	2
Asthma, Bronchial [description not available]	5.28	8
Eczema, Atopic [description not available]	4.87	12
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	3.42	2
Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	5.28	8
Dermatitis, Atopic A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.	4.87	12
Congenital Zika Syndrome [description not available]	2.25	1
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1
ER-Negative PR-Negative HER2-Negative Breast Cancer [description not available]	2.25	1
Breast Cancer [description not available]	2.86	3
Breast Neoplasms Tumors or cancer of the human BREAST.	2.86	3
Triple Negative Breast Neoplasms Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.	2.25	1
Palmoplantaris Pustulosis [description not available]	2.5	2
Dermatitis Seborrheica [description not available]	2.15	1
Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.	2.5	2
Dermatitis, Seborrheic A chronic inflammatory disease of the skin with unknown etiology. It is characterized by moderate ERYTHEMA, dry, moist, or greasy (SEBACEOUS GLAND) scaling and yellow crusted patches on various areas, especially the scalp, that exfoliate as dandruff. Seborrheic dermatitis is common in children and adolescents with HIV INFECTIONS.	2.15	1
Contact Dermatitis [description not available]	2.17	1
Dermatitis, Contact A type of acute or chronic skin reaction in which sensitivity is manifested by reactivity to materials or substances coming in contact with the skin. It may involve allergic or non-allergic mechanisms.	2.17	1
Chronic Illness [description not available]	2.17	1
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	2.17	1
Anorexia The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.	2.17	1
Disease Exacerbation [description not available]	2.54	2
Autosomal Dominant Juvenile Parkinson Disease [description not available]	2.21	1
Nerve Degeneration Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.	2.21	1
Idiopathic Parkinson Disease [description not available]	2.61	2
Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)	2.61	2
Parkinsonian Disorders A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.	2.21	1
Autism Spectrum Disorder Wide continuum of associated cognitive and neurobehavioral disorders, including, but not limited to, three core-defining features: impairments in socialization, impairments in verbal and nonverbal communication, and restricted and repetitive patterns of behaviors. (from DSM-V)	2.21	1
Choreoathetosis Self-Mutilation Hyperuricemia Syndrome [description not available]	2.21	1
Lesch-Nyhan Syndrome An inherited disorder transmitted as a sex-linked trait and caused by a deficiency of an enzyme of purine metabolism; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE. Affected individuals are normal in the first year of life and then develop psychomotor retardation, extrapyramidal movement disorders, progressive spasticity, and seizures. Self-destructive behaviors such as biting of fingers and lips are seen frequently. Intellectual impairment may also occur but is typically not severe. Elevation of uric acid in the serum leads to the development of renal calculi and gouty arthritis. (Menkes, Textbook of Child Neurology, 5th ed, pp127)	2.21	1
Acute Liver Injury, Drug-Induced [description not available]	2.08	1
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	2.08	1
Cough A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.	2.5	2
Allergic Encephalomyelitis [description not available]	2.08	1
MS (Multiple Sclerosis) [description not available]	2.08	1
Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)	2.08	1
Eosinophilia, Tropical [description not available]	2.08	1
Eosinophilia Abnormal increase of EOSINOPHILS in the blood, tissues or organs.	2.08	1
Pleurisy INFLAMMATION of PLEURA, the lining of the LUNG. When PARIETAL PLEURA is involved, there is pleuritic CHEST PAIN.	2.5	2
Adjuvant Arthritis [description not available]	2.51	2
Carcinoma, Non-Small Cell Lung [description not available]	2.1	1
Cancer of Lung [description not available]	2.1	1
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.1	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.1	1
Convalescence The period of recovery following an illness.	2.1	1
Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.	2.76	3
Choroid Neovascularization [description not available]	2.1	1
Age-Related Macular Degeneration [description not available]	2.1	1
Macular Degeneration Degenerative changes in the RETINA usually of older adults which results in a loss of vision in the center of the visual field (the MACULA LUTEA) because of damage to the retina. It occurs in dry and wet forms.	2.1	1
Acute Promyelocytic Leukemia [description not available]	2.1	1
Leukemia, Promyelocytic, Acute An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.	2.1	1
Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma.	2.52	2
Alveolitis, Fibrosing [description not available]	2.52	2
Pneumonia Infection of the lung often accompanied by inflammation.	2.52	2
Pulmonary Fibrosis A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.	2.52	2
Cancer of Mouth [description not available]	2.11	1
Condition, Preneoplastic [description not available]	2.11	1
Experimental Radiation Injuries [description not available]	2.11	1
Mucositis, Oral [description not available]	2.11	1
Mouth Neoplasms Tumors or cancer of the MOUTH.	2.11	1
Precancerous Conditions Pathological conditions that tend eventually to become malignant.	2.11	1
Stomatitis INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.	2.11	1
Nasal Diseases [description not available]	2.11	1
Parodontosis [description not available]	2.13	1
Pericementitis [description not available]	2.13	1
Alveolar Bone Atrophy [description not available]	2.13	1
Periodontal Diseases Pathological processes involving the PERIODONTIUM including the gum (GINGIVA), the alveolar bone (ALVEOLAR PROCESS), the DENTAL CEMENTUM, and the PERIODONTAL LIGAMENT.	2.13	1
Periodontitis Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology)	2.13	1
Acute Pain Intensely discomforting, distressful, or agonizing sensation associated with trauma or disease, with well-defined location, character, and timing.	2.15	1
Pink Eye [description not available]	2.05	1
Conjunctivitis INFLAMMATION of the CONJUNCTIVA.	2.05	1
Rhinitis, Allergic, Nonseasonal [description not available]	3.66	3
Rhinitis, Allergic, Perennial Inflammation of the mucous membrane of the nose similar to that found in hay fever except that symptoms persist throughout the year. The causes are usually air-borne allergens, particularly dusts, feathers, molds, animal fur, etc.	3.66	3
Hay Fever [description not available]	2.96	1
Rhinitis, Allergic, Seasonal Allergic rhinitis that occurs at the same time every year. It is characterized by acute CONJUNCTIVITIS with lacrimation and ITCHING, and regarded as an allergic condition triggered by specific ALLERGENS.	2.96	1
Anasarca [description not available]	2.73	3
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	2.73	3
Benign Mastocytoma [description not available]	2.05	1
Canine Diseases [description not available]	2.05	1
Dermatoses [description not available]	2.05	1
Skin Diseases Diseases involving the DERMIS or EPIDERMIS.	2.05	1
Airway Remodeling The structural changes in the number, mass, size and/or composition of the airway tissues.	2.05	1
Bronchial Hyperreactivity Tendency of the smooth muscle of the tracheobronchial tree to contract more intensely in response to a given stimulus than it does in the response seen in normal individuals. This condition is present in virtually all symptomatic patients with asthma. The most prominent manifestation of this smooth muscle contraction is a decrease in airway caliber that can be readily measured in the pulmonary function laboratory.	2.47	2
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	2.06	1
Erythema Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of disease processes.	2.06	1
Malignant Melanoma [description not available]	2.06	1
Cancer of Skin [description not available]	2.06	1
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	2.06	1
Skin Neoplasms Tumors or cancer of the SKIN.	2.06	1
Dermatitis Any inflammation of the skin.	2.07	1
Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.	2.99	1
Allergic Conjunctivitis [description not available]	2.07	1
Conjunctivitis, Allergic Conjunctivitis due to hypersensitivity to various allergens.	2.07	1
Gastric Ulcer [description not available]	2.07	1
Stomach Ulcer Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).	2.07	1
Allergic Contact Dermatitis [description not available]	2.07	1
Dermatitis, Allergic Contact A contact dermatitis due to allergic sensitization to various substances. These substances subsequently produce inflammatory reactions in the skin of those who have acquired hypersensitivity to them as a result of prior exposure.	2.07	1
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	2.02	1
Acute Disease Disease having a short and relatively severe course.	2.02	1
Airway Hyper-Responsiveness [description not available]	2.03	1
Diseases of Immune System [description not available]	2.95	1
Immune System Diseases Disorders caused by abnormal or absent immunologic mechanisms, whether humoral, cell-mediated, or both.	2.95	1
Nerve Pain [description not available]	2.03	1
Neuralgia Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.	2.03	1

chemdatabank.com